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 Chronic kidney disease (CKD) is a life threatening condition with high 
risk of pre-term death and need for dialysis. The population prevalence of CKD 
has been estimated to 10-13% for both Europe and the USA. We investigated if 
analgesic use, occupational lead exposure and other patient characteristics were 
related to decline in kidney function in a population-based cohort of 920 patients 
with CKD. We also studied how survival related to timing of dialysis initiation.  
 The inclusion took place in Sweden between May 20 1996 and May 31 
1998. All Swedish-born patients, 18-74 years old, who had been tested with a 
serum creatinine ≥300µmol/l for men and 250µmol/l for women for the first time 
were included and interviewed. At three occasions, during 1996-1998, age and 
sex-matched controls were included from the general population for comparison. 
Through linkages with the Swedish Renal Registry, the Swedish Population and 
Cause of Death Registry, and the patients’ medical records we followed these 
patients until either death, start of renal replacement therapy (RRT [dialysis or 
transplantation]) or Dec 31 2005.  
 At the end of the follow-up 756 patients had initiated RRT while 46 
were still alive and without RRT. After one and three years, the proportion of 
patients alive and without RRT was 64% and 29%, respectively. The mean 
unadjusted decline in estimated glomerular filtration rate (eGFR) was 
9.0ml/min/1.73 m2 per year, while the median decline was 5.1ml/min/1.73 m2 per 
year. Younger patients, those with higher blood pressure, and more albuminuria 
had a faster decline in glomerular filtration rate. However, patients with regular 
acetaminophen or aspirin use progressed with -5.1/-4.4 ml/min/1.73m2 compared 
to -5.3/-5.1 ml/min/1.73m2 among non-regular users. There was no difference in 
progression rate among patients with a high lifetime cumulative analgesic use 
compared to non-exposed. We could not detect any significant risk of CKD with 
occupational lead-exposure (OR 0.97, 95% CI 0.7-1.4). Neither did patients who 
had been occupationally exposed to lead differ in progression rate or risk for 
RRT compared to those who had never been lead exposed.  
 Mortality was high both before and after dialysis, one and five-year 
survival was 97% and 61%. Compared to the general population the adjusted 
standardized mortality ratio was 8.3 (95% CI 7.5-9.2). Patients with diabetic 
nephropathy, low body mass index, and high co-morbidity score, blood pressure, 
and albuminuria had a significantly higher risk of death. Mortality increased by 
eGFR and progression rate. The HR (death) for eGFR <7.5 ml/min/1.73 m2 was 
4.65 (95% CI 1.28, 9.49) compared to non-RRT patients with eGFR 7.5-
10ml/min/1.73 m2. After dialysis start mortality increased further; the HR for 
patients who had started dialysis was 2.64 (95% CI 1.80, 3.89) relative to patients 
who had not yet started dialysis. However, timing of dialysis initiation was not 
associated with survival. The HR for patients initiating dialysis with an eGFR 
<7.5 ml/min/1.73 m2 was 0.84 (95% CI 0.64-1.10) relative to those who started 
dialysis at higher eGFR. In summary, most patients with Stage 4 or 5 CKD 
progress to RRT, and the factors that most importantly affect the progression rate 
are age, blood pressure and proteinuria. Mortality is very high in this population, 
relates to eGFR and does not improve after initiation of dialysis. 
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1 GENERAL INTRODUCTION 
 
Chronic kidney disease (CKD) is a worldwide killer. Not only does a poor renal 
function cause patients to die of uremia, but there is also a strong association 
between CKD and cardiovascular disease. This association, which is present also 
in earlier stages of CKD, has increased the awareness of the importance of a 
normal kidney function. In industrialized countries, most patients with renal 
failure receive renal replacement therapy (RRT) with dialysis or kidney 
transplantation. In many developing countries, uremia is lethal because of the 
lack of economy and the necessary infrastructure needed to support any type of 
RRT. Although countries in the industrialized world are willing to pay for 
dialysis, the cost is increasing every year. One reason may be the increasing RRT 
demand. In the United States the incidence of end-stage renal disease (ESRD) 
was 354 per million population-years in 2007 compared to 300 million per 
population-years in 1996 and 150 million per population-years in 1986.[1] The 
incidence is increasing more among the elderly (10.4% annual increase for those 
age 75 years and older and 5.5% annual increase for those age 20-44 years). The 
overall incidence in Europe was 125 per million population-years in 2006 
compared to 110 per million population-years in 1997.[2, 3] The annual increase 
was estimated to 4.8% during the 1990’s [4] but seems to have stabilized recently 
at 0.6%. The stabilization is mainly due to lower incidence rates among the 
elderly.[5] In Sweden, the overall incidence was 117 per million population-years 
in 2006 and 115 per million population-years in 1997.[6] The RRT prevalence 
has increased even more during the latest decades; the annual increase in Europe 
is estimated to 2.7%.[5] The reason may be that survival has improved overall in 
RRT, and thereby treatment duration. Another reason may be a trend to initiate 
RRT at higher eGFR, which could lead to higher apparent incidence rates [7] and 
higher prevalence.  
 
1.1 BASIC KIDNEY FUNCTION 
 
The kidneys are central in both fluid management and the removal of toxic waste 
products (uremic toxins). The blood pressure and water balance is regulated 
through direct effects in the renal vessels (auto regulation, oncotic and 
hydrostatic pressure gradient) and through the renal endocrine system called the 
renin-angiotensin system (RAS). The kidneys produce the hormone 
erythropoeitin needed to stimulate the red blood cell production. They also 
express the enzyme 1,25 hydroxylase, which converts inactive D-vitamin to 
active D-vitamin. [8] 
 
The renal blood flow is approximately 20% of the cardiac output (1.1-1.3 L/min).  
The blood volume is filtered through the renal capillaries and the renal 
glomerulus’s to form the primary urine. About 20% of the plasma is filtered; the 
normal glomerular filtration rate (GFR) is approximately 125 ml/min. The 
primary urine is transported in the tubular system, in which most of the water and 
electrolytes are re-absorbed to form the final urine. The functional unit of the 
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kidney (the glomerulus’s and its connecting tubular system) is called “the 
nephron”. [9] 
 
























This figure was published in Rang and Dale, Pharmacology 6th edition, ISBN 
0443069115. Used with permission from Elsevier.  
 
 
Activation of the RAS is essential in renal diseases and hypertension. The renal 
hormone Renin is secreted from the juxtaglomerular cells near the afferent 
arteriole of the glomeruli. Renin promotes the transformation of angiotensinogen 
to angiotensin I. Further conversion to angiotensin II is enhanced by the enzyme 
ACE (angiotensin converting enzyme) in lung and endothelial cells. Angiotensin 
II activates the Angiotensin I receptor. The result is vasoconstriction, stimulation 
of sympathic nerves, salt and water retention, resulting in increased blood 
pressure, and decreased natriuresis.[10] 
 
 
1.2 CLASSIFICATION OF CKD 
 
The terminology for patients with declining renal function has varied over time 
and situation. Classification of renal diseases used to be categorized by the 
primary cause. In 2002, the National Kidney Foundation and Kidney Disease 
Outcomes Quality Initiative (NKF/KDOQI) published their guidelines with the 
purpose to unify the classification and definition of CKD.[11] The new 
   3 
classification system is based on the level of glomerular filtration rate (GFR). 
The accepted definition of CKD is kidney damage for ≥3 months, defined by 
structural or functional abnormalities of the kidney (pathological abnormalities or 
abnormalities of imaging or the composition of blood or urine), with or without 
decreased GFR. CKD is also defined as GFR <60 ml/min/1.73m for ≥3 months, 
with or without kidney damage. There are currently five stages of CKD (Table 1).  
 
Table 1. Definition and classification of CKD stages  
 
Stage 
 Description GFR (ml/min/1.73m
2) 
1 
 Kidney damage with normal or ↑GFR >90 
2 
 Kidney damage with mild ↓ GFR 60-89 
3 
 Moderate ↓ GFR 30-59 
4 
 Severe ↓ GFR 15-29 
5 
 Kidney failure with or without dialysis <15 (D+/D-) 
 
 
Based upon the current classification system, the overall population prevalence of CKD 
has been estimated to 10-13%.[12, 13] The prevalence is 3.1%, 3.4%, 4.5%, and 0.16% 
for Stage 2-5 respectively. This prevalence is similar in Norway and the United States in 
spite of the much higher incidence of ESRD in the United States. Age is strongly related 
to likelihood of having CKD, 17.9% and 0.71% of the subjects in the oldest age category 
(>70 years) had CKD stage 4 and 5, compared to 0.2% and 0.02% among 20-39 year 
olds. 
 
Recently there has been a debate because some nephrologists believe that the current 
classification system over- and misdiagnoses CKD.[14-17] Observations seem to indicate 
that the reported prevalence of CKD in the general population is too high compared to 
the observed incidence of ESRD.[14] A recent meeting has suggested both a split of stage 
3 at GFR 45 ml/min and stratification by albuminuria, because of its strong relationship 
to overall and cardiovascular mortality and better prediction of progress to ESRD.[18]  
 
1.3 END-STAGE RENAL DISEASE 
 
As renal function declines, it is eventually time to start RRT (hemodialysis, 
peritoneal dialysis or kidney transplantation). The decision to start is usually 
based upon a combination of the GFR, the patient’s uremic symptoms (e.g. 
nausea, weight loss, vomiting, itching, diarrhea, fluid retention) and the patient’s 
and doctor’s preference. The US NKF/KDOQI guidelines from 2002 state that 
dialysis should be considered when Kt/Vurea is 2.0, which approximates a GFR of 
10.5 ml/min.[11] In the up-dated version from 2006 it is suggested that dialysis 
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could start even at GFR above 15 ml/min if needed.[19] European guidelines 
state that dialysis should be prepared when GFR is 8-10 ml/min and initiated no 
later than eGFR 6 ml/min. [20] Before the introduction of these guidelines GFR 
was generally lower at dialysis initiation. Since then, the trend has been towards 
an earlier start. In the United States between 1996 and 2005, the percentage of 
patients starting at an eGFR above 10 ml/min/1.73 m2 in the United States 
increased from 19% to 45%.[21] Although dialysis treatment is an option for 
almost everyone in the developed countries, some elderly patients with severe 
CKD are still treated conservatively. Overall, elderly patients who initiate 
dialysis show a better one year and two year survival compared to patients treated 
conservatively, but in selected groups with a higher overall co morbidity score, 
conservative treatment may be an equal alternative.[22, 23]  




2.1 CAUSES OF CKD 
 
There are many causes of CKD, the most common cause being diabetic nephropathy. [6] 
Diabetic patients represent 24% of incident ESRD patients and 19% of the prevalent 
dialysis population in Sweden. The second most common cause of CKD is hypertension. 
About 20% of the incident ESRD patients were classified as having nephrosclerosis, 
followed by glomerulonephritis (11%), hereditary diseases (9%), and pyelonephritis 
(4%). The cause of CKD is often unknown. In Sweden, the proportion of patients with 
unknown causes of uremia is 7%.[6] The primary renal disease diagnosis is most often 
based upon the pathology report of the kidney biopsy. However, there are many other 
factors contributing to the development of CKD; environmental toxins, occupational 
exposures, drug use, diet, smoking, and alcohol habits. These factors may have an 
additional negative effect on already established CKD, or contribute to the development 
of de novo CKD.  
 
2.2 GLOMERULAR FILTRATION RATE ESTIMATIONS 
 
Measurements of renal function or GFR are central in the classification of kidney 
diseases.[11] The gold standard for GFR measurement uses the fructose 
polysaccharide inulin.[24] Inulin is infused intravenously into the patient’s blood 
and measured in blood and urine after a given time. The GFR is calculated using 
the formula  
GFR=Uin×V/ Pin  
in which Uin is the urine concentration, Pin is the plasma concentration and V is 
the amount of urine excreted per time unit. There are also other methods that 
nowadays are more frequently used to measure glomerular filtration rate, like 
125I-iothalamate, 99mTc-DTPA, and iohexol.[25] 
However, these methods are inconvenient and expensive to use in everyday 
clinical practice. Instead, endogenous substances such as creatinine, urea, and 
cystatin C are measured in urine or blood.[26] Serum creatinine (from the Greek 
kreas, flesh) is the most widely used marker. It is a cheap test included in almost 
every standard blood sampling for electrolyte balance. Unfortunately, there are 
several important limitations.[25] Serum creatinine (S-Cr) is a breakdown 
product of creatine phosphate in muscle and produced at a constant rate by the 
body under steady-state conditions. It is freely filtered in the kidneys, but a small 
amount is actively secreted and this proportion becomes more important if the 
filtration rate decreases. The S-Cr level is a general marker of the nutritional 
status of the patient. It can be affected by the individual muscle mass, recently 
ingested meat and the patient’s fluid balance. 
Several attempts have been made to produce a reliable equation to estimate GFR 
from the S-Cr value. The first more widely spread formula used to estimate renal 
function is the Cockcroft-Gault formula.[27] 
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Creatinine clearance = (140-age*bodymass [kg] /plasma-creatinine [mg/dL] * 
72) *0.85 [if female] 
 
The Cockcroft-Gault formula estimates the creatinine clearance, which is not 
corrected by body surface area, and thus the absolute value of the filtration rate. 
Due to the increased creatinine secretion, the creatinine clearance usually 
overestimates GFR when the GFR is low. In the year 1999, a new formula was 
presented which standardized the GFR to body surface area (ml/min/1.73m2).[28] 
The formula was developed from the Modification of Diet in Renal Disease 
(MDRD) study, which consisted of 1,628 non-transplanted CKD-patients with 
non-diabetic renal disease. 
 
eGFR= 186*[S-Cr]-1.154 *[Age]-0.203 *[0.742 if female]*[1.212 if African 
American] 
 
The MDRD equation was re-expressed in 2006. The new equation is adjusted to a 
standardized creatinine calibration (eGFR = 175 x (Standardized S-Cr)-1.154 x 
(age)-0.203 x (0.742 if female) x (1.210 if African American) which gives 
approximately 5% lower values of the S-Cr.[29] There are many comparisons 
between the MDRD equation and the Cockcroft-Gault formula. Currently, the 
MDRD equation is more widely used in research, and it is believed to give a 
more accurate estimate of the GFR compared to the Cockcroft-Gault formula, 
especially for obese and older individuals.[26, 30] The bias compared to inulin 
clearance is quite large with both equations, but for CKD stage 5 it is less with 
the MDRD equation.[31] Lately, yet another equation has been developed. This is 
called the CKD-EPI and produces higher eGFR values in the high eGFR range 
(>60 ml/min/1.73 m2), and lower eGFR values in the lowest range.[32]  
 
The serum levels of Cystatin C (a proteinase inhibitor) depend on the glomerular 
filtration. Cystatin C is produced by all human cells and has become an 
increasingly more popular endogenous marker for GFR during the 21st century. It 
has better precision among patients with mild CKD and is less sensitive to food 
intake, age, sex, and body composition.[33] The validity of the GFR estimate is 
however highly dependent on the laboratory method and currently several 
estimating equations are used for the different analyses methods. An international 
calibrator is under development, which will improve the standardization of the 
analysis.[34] 
 
2.3 RISK FACTORS FOR CKD AND DECLINE IN RENAL FUNCTION 
 
The GFR deteriorates after the age of 20-30 years, with a normal rate of on 
average 1 ml/min per year. The decline in GFR (progression rate) may vary 
substantially between individuals. Among patients with CKD, the progression 
rate is usually faster than in the general population.[35, 36]  Although it is 
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sometimes difficult to treat the primary renal disease itself, nephrologists try to 
reduce the progression rate, reduce albuminuria, and prevent the patient from 
need of dialysis. 
 
Loss of renal function may be engraved by a number of causes: primary renal 
diseases, diabetes, hypertension, diet, nephrotoxic drugs and environmental 
toxins. The multi-factorial etiology of renal function loss is sometimes referred to 
as the “multi-hit hypothesis”.[37] Loss of nefron mass results in glomerular 
hypertension in the remaining nephrons due to compensatory hyper filtration. 
[38]The consequence of renal hyper filtration is increased mesangial cell 
proliferation and over-expression of cytokines. A loss of more than 50% of the 
nephrons is associated with risk of developing proteinuria and severe CKD. The 
elevated intra-glomerular pressure correlates to increased urine albumin 
excretion. These proteins are reabsorbed in the proximal tubule, and induce 
activation of the intra-renal angiotensin converting enzyme and enlarged cytokine 
production.[39] Cytokines induce fibrosis, apoptosis and monocytic infiltration 
and ultimately leads to cell death and glomerulosclerosis. [40] It has been 
demonstrated that macrophage and myofibroblast infiltration in the interstitium 
correlates with the degree of renal function. [41] Macrophages produce more 
cytokines such as IL-6, TNF-α and express vascular endothelial growth factor 
while myofibroblasts express receptors for profibrogenic cytokines such as TGF-
β and platelet-derived growth factor, which induces even more fibrosis and 
ultimately apoptosis. 
 
2.3.1 Hypertension and proteinuria 
 
One of the first risk factors found to increase the progression rate was 
hypertension. However, blood pressure is not merely a risk factor for 
progression; it is also a primary cause of CKD and a consequence of the disease. 
Due to the kidneys’ close connection to the regulatory RAS system, up to 75% of 
CKD patients have elevated blood pressure. Lowering the blood pressure reduces 
the risk for progressive renal disease in CKD of different etiologies. [36, 42, 43] 
Fifteen years ago it was demonstrated that proteinuria is an important effect-
modifier of hypertension-related progressive kidney disease among CKD 
patients.[36] The MDRD study showed that patients with greater baseline 
proteinuria excretion had a greater beneficial effect of a lower blood pressure 
target on the mean progression rate. This study, along with others formed the 
present KDIGO guidelines which have different goals for different levels of 
proteinuria.[19, 44] The target blood pressure for CKD patients with 0.25-1g 
proteinuria/24h is <130/80mmHg, a limit that is below the general goals for the 
treatment of hypertension. The target is even lower (<125/75mmHg) for patients 
with diabetes, and higher levels of proteinuria. Often multiple antihypertensive 
agents are required to reach the targets. 
 
Proteinuria or albuminuria is also an independent risk factor for disease 
progression. Just as with hypertension, it is a consequence of CKD. Proteinuria 
may develop as a result of impairment of the renal glomerular membrane, or 
because of impairment of the renal tubular re-absorption. Whichever the starting 
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point, proteinuria induces complement activation and the inflammatory response 
in tubular epithelial and tubular-interstitial cells responsible for the progressive 
glomerulosclerosis.[39] In addition, in the general population albuminuria is an 
important marker for the risk of progressing CKD. The HR for progression to 
ESRD was 18.50 (95% CI 9.9-34.7) for individuals with microalbuminuria and 
193.70 (95% CI 94.6-396.7) for individuals with macroalbuminuria compared to 
those with normal albumin/creatinine ratio.[45]  
 
Angiotensin converting enzyme (ACE) inhibitors, and Angiotensin II receptor 
blockers (ARB), have emerged as corner-stone drugs in the treatment of both 
hypertension and proteinuria. First demonstrated to slow progression rate and 
prevent ESRD among patients with diabetes, these drugs were soon shown to 
have similar effects for CKD patients of different etiologies. [42, 46-48] Both 
ACE inhibitors and ARB lower the intra-glomerular pressure and reduce hyper-
filtration, blood pressure, and proteinuria.[49] The protective effects seem to go 
beyond the blood pressure lowering, as has been demonstrated in comparisons 
with other antihypertensive agents.[43, 50] Some studies have investigated the 
effect of adding an ARB to an ACE-inhibitor and shown an additional effect on 
protein excretion and TGF-β levels[51] as well as progression rate in chronic 
glomerular diseases.[52]  
 
2.3.2 Age and gender 
 
Age contributes to the progress of CKD. However, the question of whether the 
definition for CKD should be different for older patients remains unanswered. Is 
CKD a part of the normal aging process, or is it a disease? Today, classification 
of CKD is the same regardless of age, although voices have been raised to change 
this.[16] Most studies have claimed that age is a risk factor for a faster 
progressing rate, but there are also results showing the opposite. Younger age has 
been associated with faster decline of GFR or progression to RRT in selected 
populations of type1 diabetes [53] and mesangio-proliferative 
glomerulonephritis[54]. In a study of patients with hypertension related kidney 
disease older patients progressed more slowly.[55] Male sex, on the contrary, has 
been established as a risk factor for faster progression in several epidemiological 
studies.[56] Among potential kidney donors, 20-50 years old, GFR fell by 8.7 
ml/min/1.73 m2 per decade for men but not for women.[57] The reason for this 
relationship is not obvious but differences in sex hormones have been suggested 
to affect renal function and progression rate.[58] It is however not clear if it is the 
lack of estrogen or the presence of testosterone that makes the difference. 
Overall, CKD is much more common among men than women. Men represent 
about 64% of the Swedish ESRD population in 2009.[6] 
 
2.3.3 Obesity  
 
Obesity is a risk factor for CKD, even if disregarding the closely associated 
diseases diabetes and hypertension.[59-62]  High BMI is associated with a 
greater risk of developing nephropathy and proteinuria also among diabetics or 
hypertensives.[63, 64] Among subjects with non-diabetic metabolic syndrome, 
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waist circumference is an independent risk factor for the development of 
albuminuria.[65]Obesity may accelerate the progression rate among subjects with 
other types of primary renal diseases.[66] Reversely, weight reduction (after 
gastric bypass) has lead to a decline in proteinuria or stabilized GFR in small 
studies of both subjects with and without CKD.[67, 68] The patho-physiological 
disturbances seen in the kidneys with obesity are renal hyper-filtration and focal 
glomerulosclerosis.[69] The effects are probably mediated through vasodilatation 
of the afferent arterioles, leptin-induced cellular proliferation and stimulation of 
cytokines, and up-regulated RAS.[70, 71]  
 
2.3.4 Smoking and alcohol intake 
 
Smoking is now considered to be a risk factor for both the development, and for 
the progression of established CKD.[72, 73] The strongest associations have so 
far been noted among diabetics and hypertensives, [73, 74] but there are studies 
indicating that smoking is detrimental to renal function also in other primary 
renal diseases [75] and in the general population.[76, 77] In epidemiological 
case-control and cohort studies, smoking has been associated with albuminuria, 
rise in serum creatinine, CKD, and risk of ESRD.[72, 78-80] Smoking is one of 
the factors linked to lower socio-economic status responsible for the over 
representation of people with low educational level among ESRD patients. Other 
factors known to be influenced by socio-economic status and capable of 
modifying the relationship to CKD are presence of obesity, diabetes type II, 
alcohol use, occupational exposures, and dietary factors. The relationship 
between high alcohol consumption and CKD is not clear. Although one study 
showed increase in albuminuria [81] with heavy alcohol use, other studies have 
seen no effect [82] or favorable effects [81, 83] on the decline in GFR among 
healthy subjects.  
 
2.3.5 Protein intake 
 
It has been known for a long time that reduction in protein intake reduces uremic 
symptoms among patients with severe CKD. Before dialysis was invented and 
implemented, dietary treatment was the only option for most CKD patients. More 
than 50 years ago it was first suggested that a low-protein diet may be beneficial 
for patients with CKD.[84] Experiments in both animals and in humans has then 
demonstrated that a high protein load causes acute effects in the kidneys by 
increasing the renal blood flow and inducing hyper filtration.[38, 85-87] 
However, a long-term detrimental effect on the kidneys of a high chronic protein 
intake has been more difficult to show. In the Nurses health study, a high intake 
of animal protein was associated with presence of microalbuminuria but not 
decline in eGFR over 11 years. Two or more servings of red meat per week was 
associated with microalbuminuria (Odds ratio (OR) 1.51, 95% CI 1.01-2.26) 
compared to less than one serving per week.[88] Among CKD patients there have 
been several trials with low protein diets with diverse results. The MDRD study 
did not really show a convincing effect in the first publication.[89] In post-hoc 
analyses, results from that trial showed that protein reduction could have some 
effect on the progression rate among patients with severe CKD, but less effect in 
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earlier stages.[90] After that, there have been meta-analyses suggesting a 
beneficial effect of low protein diet in patients with moderate and severe 
disease.[91-93] The beneficial effect from protein restriction mainly appear to be 
a delay in time to dialysis rather than an actual decrease in the progression rate. 
The protein restricted diet possibly decreases the production and retention of 
uremic toxins, and thereby symptoms of uremia, prompting initiation of dialysis 
treatment. Today, protein restriction (0.6g/kg/24 hours) together with 




2.4 RISK FACTORS FOR MORTALITY 
 
2.4.1 Mortality among CKD patients 
 
As in the general population, traditional risk factors such as smoking, 
dyslipidemia, diabetes, and hypertension predict mortality and morbidity among 
CKD patients in the early stages (1-3). However, for patients with severe kidney 
damage and patients with ESRD other risk factors (inflammation, endothelial 
dysfunction, protein-energy wasting (PEW), and vascular calcification) seem to 
play a far greater role in prediction of the cardiovascular risk.[94] A complicating 
fact is that the traditional risk factors are modified as renal function declines. 
Some of them, for example hypertension and volume-overload become 
increasingly frequent while others such as total cholesterol and protein intake 
decrease spontaneously.  
 
Level of GFR is an independent risk factor for death. The increased 
cardiovascular risk starts already at GFR <75 ml/min and further increase as renal 
function declines.[95, 96] In the United States, the age and sex adjusted 
standardized mortality rate was 1.08 (eGFR 45-59 ml/min/1.73 m2), 4.76 (eGFR 
30-44 ml/min/1.73 m2), 11.36 (eGFR 15-29 ml/min/1.73 m2) and 14.14 (eGFR 
<15 ml/min/1.73 m2).[97] In one study the relative risk (RR) of cardiovascular 
mortality associated with eGFR <70 ml/min/1.73m2 was 1.68 (95% confidence 
interval [CI] 1.33-2.13) compared to eGFR >90 ml/min/1.73m2.[98] In fact, the 
probability of dying from cardiovascular disease is much greater than the 
probability of progressing to ESRD for most CKD patients in early stages. [99, 
100]  
 
Albuminuria modifies the relationship between eGFR and mortality.[101] 
Albuminuria also seems to be an independent risk factor of death, cardiovascular 
events and heart failure regardless of the GFR.[102] The level of 
macroalbuminuria has been linked to increased mortality, but also 
microalbuminuria (<300mg/24h) increases the risk of fatal and non-fatal 
cardiovascular events regardless of renal function and presence of diabetes.[103] 
Lately it has been observed that the risk of death and cardiovascular events is 
increased also among individuals with cut-off levels less than the ordinary limits 
for microalbuminuria.[104] Since the relationship between urinary albumin-
creatinine ratio and mortality is virtually linear it has been suggested that 
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microalbuminuria is more a marker of generalized endothelial damage than an 
expression for a kidney disease. [105] Chronic inflammation is also associated 
with mortality. Elevated markers of inflammation such as CRP and fibrinogen 
have been observed to correlate to fatal and non-fatal cardiovascular events 
among patients with Stage 3-4 CKD.[106] Notably, the CRP levels themselves do 
not seem to be a risk factor. Individuals with an elevated CRP due to gene 
polymorphism without the corresponding inflammation have not the same 
increased cardiovascular risk seen in inflammatory diseases. [107] Furthermore, 
there are studies showing that albuminuria and inflammation together have a 
greater association to hypertension, atherosclerosis, and metabolic abnormalities 
than albuminuria alone.[108-110] In the general population, the risk for all-cause 
mortality was four times greater among subjects in the highest quartile of both 
albumin-creatinine ratio and fibrinogen compared to the lowest.[111] 
 
There are many plausible explanations for the link between reduced renal 
function, albuminuria, inflammation and mortality. Endothelial dysfunction 
seems to be one of the markers of cardiovascular injury that is of importance 
among CKD patients, and it has been linked to both albuminuria and 
inflammation.[112] Indeed, among CKD patients there is an imbalance between 
the levels of circulating endothelial cells and endothelial progenitor cells, which 
are mobilized from the bone marrow as a result of vascular injury.[113] Among 
CKD patients the number of endothelial progenitor cells is decreased which may 
cause impaired neo-vascularization of ischemic vascular tissue.[114] Surrogate 
markers of endothelial dysfunction, e.g. intracellular adhesion molecule 1, are 
strongly associated to mortality among ESRD patients.[115] Other factors, such 
as increased oxidative stress and the accumulation of post-synthetically modified 
proteins have also been suggested to promote CKD-associated inflammation.[94] 
 
When GFR declines it is followed by a spontaneous decrease in protein and 
energy intake as well as falling serum total cholesterol and serum transferrin 
levels.[116] In normal skeletal muscle turnover, there is a balance between 
skeletal muscle synthesis and breakdown. In catabolic states and uremia the 
breakdown exceeds the synthesis which results in muscle wasting. The state of 
PEW seen among CKD patients is closely linked to both inflammation and 
cardiovascular outcomes.[117] Patients judged to be malnourished by subjective 
global assessment demonstrated higher CRP and fibrinogen levels as well as 
increased frequency of carotid plaques and calculated intima-media area.[117] 
The same malnourished patients also exhibit signs of more vascular endothelial 
activation, and associations to higher all-cause mortality[118]. A number of other 
factors promote PEW such as metabolic acidosis and excessive angiotensin II. 
Impaired insulin/IGF-1 signaling may also be of importance.[119] As S-Cr levels 
reflect muscle mass, these levels are generally lower among malnourished 
patients. Low S-Cr has been independently associated to mortality in 
epidemiological studies of patients initiating dialysis.[120] 
 
Changes in the mineral and bone metabolism starts early in the course of renal 
function decline. Elevated levels of serum phosphate have been associated with 
increased mortality among CKD patients.[35] Prescence of vascular calcification 
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has been associated with serum phosphate within the normal range. Among Stage 
3 CKD patients, each 1-mg/dl (0.32 mmol/l) increment in serum phosphate 
concentration was associated with a 21% greater prevalence of coronary artery 
calcification and 62% greater prevalence of mitral valve calcification.[121] An 
estimate of the vascular calcification is the abdominal aortic calcification (AAC) 
score, which relies on lateral lumbar radiographs. The AAC score is highly 
predictive of cardiovascular mortality in several studies including the general 
population and dialysis patients.[122, 123] [124] 
 
2.4.2 Mortality among dialysis patients 
 
Prevalent patients in dialysis, regardless of dialysis modality, have nearly seven 
times higher mortality compared to the general population. The expected 
remaining lifetime in US for a 50-54 year old patient in dialysis is 6.5 years, 
compared to 29 years for a person of similar age without ESRD. However, 
survival has improved over the years, adjusting for the aging dialysis population. 
Compared to 1993-1997, the 7-year survival has increased by 7.5% to 38%. [125] 
The overwhelming cause of death is cardiovascular disease, and this is especially 
noted for the elderly. Mortality is greatest during the third month after dialysis 
initiation. Although overall mortality has decreased among dialysis patients, 
mortality during the first 3-4 months is still higher today than during the 
1980’s.[125, 126] Traditional risk factors for cardiovascular disease and death 
are not obviously related to mortality and morbidity among dialysis patients. The 
reasons may be that many of these markers such as cholesterol levels, 
hypertension and obesity change along the disease trajectory because of the renal 
function decline. 
 
The number of obese patients starting dialysis has increased and in the US today 
more than 30% have a BMI >30 kg/m2 at initiation. The incidence of ESRD 
caused by diabetes has increased more than 55% among 30-39 year old African 
Americans since the year 2000.[126] Although obesity is associated with 
increased mortality in the general population, a paradoxical association between 
BMI and mortality has been found repeatedly among dialysis patients.[127, 128] 
The correlation between higher BMI and lower mortality has been observed 
across subgroups of diabetics, non-diabetics, ethnical groups, and dialysis 
modalities.[129] Furthermore, weight loss but not weight gain is associated with 
an increased risk of death.[130] On the other hand, the protective effect seems to 
be highest for obese patients with a normal or high muscle mass indicating that 
muscle protein also plays some role here.[131] Thus, PEW is a risk factor also 
among obese individuals in hemodialysis.[132] Obesity has been correlated to 
increased inflammation, oxidative stress and insulin resistance. Activated white 
adipose tissue increases the synthesis of pro inflammatory cytokines, such as IL-
8, IL-6, IL-1, and TNF-α, while regulatory cytokines are decreased. In particular 
visceral fat correlates to cytokine levels, dyslipidemia and serum leptin 
levels.[133]  
 
In contrast to the general population, the relationship with serum total cholesterol 
and low-density lipoprotein (LDL) cholesterol is the reverse. A low LDL-
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cholesterol and total cholesterol is a prognostic marker for early death among 
hemodialysis patients.[134] The LDL particle arises when very low-density lipo 
protein (VLDL) is converted to an intermediate-density lipoprotein (IDL) and 
further to form LDL. High-density lipoprotein (HDL) is needed to perform the 
last step and formed from the IDL particle. In ESRD-patients, the clearance rate 
of both the highly atherogenic IDL [135] and LDL is slower, but since the 
formation of LDL also is reduced, there is an over-representation of IDL 
particles.[136] HDL-cholesterol is generally lower than normal in patients with 
ESRD, and the low values are associated with increased cardiovascular events 
just as in the general population.[137] Inflammation decreases the levels of both 
total cholesterol and HDL while LDL has been observed to increase following an 
acute infection.[138] Thus, chronic inflammation among patients in dialysis may 
attribute to their lower cholesterol levels, regardless of renal function. 
 
The relationship between the uremic state and inflammation is even more 
pronounced among dialysis patients. Also in dialysis, inflammation is closely 
linked to PEW and death.[117] For many years, serum albumin was used as a 
proxy marker for malnutrition. Hypoalbuminemia has been a known risk factor 
for mortality among dialysis patients for a long time.[134] However, a low serum 
albumin is a poor nutritional marker as serum albumin decreases late in the 
course of starvation.[139] On the other hand, albumin is closely linked to 
inflammation, and when correcting for inflammation by using CRP, fibrinogen or 
IL-6, the relationship between serum albumin and mortality weakens.[140] It is 
believed that hypoalbuminemia among dialysis patients is caused by a lower 
albumin synthesis and a reduced possibility of down-regulating albumin 
degradation.[141] The intervention of hemodialyis may also contribute to the 
process as increased body protein breakdown has been observed but no 
subsequent increase in production during the hemodialysis session.[142] Apart 
from their effects on lipid metabolism, treatment with statins is generally 
believed to reduce inflammation and endothelial dysfunction among non-CKD 
patients. In a large randomized trial, there was however no significant effect of 
statin treatment on the rate of death, myocardial infarction or stroke among 
hemodialysis patients although both CRP and LDL-cholesterol levels were 
successfully lowered.[143, 144] 
 
Another reason for the extra-ordinary cardiovascular mortality among patients 
with ESRD is their perturbed bone and mineral metabolism. Secondary 
hyperparathyroidism and reduced possibility of phosphorus elimination causes 
serum calcium, and phosphorus to rise. Observational studies show that a high 
plasma phosphorus and calcium are independent risk factors for cardiovascular 
events and all-cause mortality.[145] The relationship for parathyroid hormone 
(PTH) is more complex; both high and low values are associated with increased 
mortality. Dialysis patients who achieve the targets for calcium, phosphate and 
PTH have improved survival [146] Treatment includes the administration of 
active vitamin D and oral phosphate binders. Lately, the calcimimetic drug 
cinacalcet has shown favorable effects on both lowering of calcium, phosphate 
and PTH. [145] Observational studies have also demonstrated favorable effects 
on cardiovascular hospitalization, fractures, parathyroidectomy, and quality of 
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life with cinacalcet treatment.[147] The AAC score predicts mortality among 
dialysis patients. Although the score probably relates to early disturbances in 
calcium and phosphate metabolism, it is not directly associated with calcium, 
phosphate or PTH when investigating prevalent dialysis patients. [148] Variables 
linked to a higher AAC score were invariably age, dialysis vintage, and co-
morbidity.  
 
One of the factors considered having impact on survival for hemodialysis and 
peritoneal dialysis patients is timing of dialysis initiation. The reason is believed 
to be through known risk factors such as PEW, which increases when GFR 
declines. Other authors argue that the dialysis procedure itself increases the risk 
for inflammation and silent myocardial ischemia.[149] The earliest studies 
investigating the effect of timing of dialysis showed that early start (at higher 
GFR) was associated with improved survival compared to late start.[150, 151] 
However, when methodological issues were considered, it became obvious that 
lead-time bias may have affected the results of the first studies. Later 
epidemiological studies were in favor of dialysis start at lower GFR values. [152-
155] However, it was found that timing of initiation was correlated to co- 
morbidity status and age; the results were thus subjected to a great probability of 
confounding by indication.[156, 157] The NKF/KDIGO Guidelines from 2002 
based their recommendation on the limit for optimal dialysis dose, which was 
Kt/V 2.0 (approximately 10.5 ml/min)[19, 158] and the observation that 
nutritional values decreased as GFR declined. Knowing the strong relationship 
between PEW and mortality, they argued that the decision to initiate dialysis 
should be based upon a combination of renal Kt/V and nutritional status of the 
patient. The introduction of these guidelines made a big impression and led to a 
rising trend in GFR at dialysis start. [159] However, the guidelines have been 
questioned; in subsequent studies it became evident that the prognosis of patients 
in dialysis was not so much related to dialysis dose, as to residual renal 
function.[21, 160] In a large randomized control trial, it was found that neither 
dialysis dose, nor type of modality or membrane significantly affected 
mortality.[161] Recently, the results from a randomized controlled trial (IDEAL) 
investigating the timing of dialysis initiation on mortality was presented.[162] 
The study did not show any benefit of earlier dialysis start. However, the study 
also demonstrated the difficulty of performing such a trial. Although the 
investigators aimed at starting dialysis at 10-14 ml/min and 5-7 ml/min for early 
and late start respectively, 76% of the patients randomized to late start in fact 
started earlier, and 11% of the patients randomized to early start started later. 
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2.5 ANALGESIC DRUG USE AND CKD 
 
Both acetaminophen (paracetamol) and phenacetin was discovered to have 
analgesic and antipyretic effects already in the 1880’s. However, because of 
phenacetin’s supposedly lower toxicity it was first introduced on the market as 
one of the compounds in “headache powder”.[163] Phenacetin increased in 
popularity, and sales grew, especially in the footsteps of the large Spanish 
influenza pandemic of 1918-1919. Apart from its analgesic effects, it also had 
psychotropic effects, which was one of the causes behind the emerging analgesic 
abuse of phenactin-containing mixtures. 
 
In 1953, it was first discovered that workers in a Swiss clock factory who abused 
analgesic drugs had a higher probability of hematuria, proteinuria and rise in 
serum creatinine.[164] Analgesic abuse was coupled to renal papillary necrosis, 
and interstitial nephritis. At the same time in Sweden, an increased incidence of 
death from uremia was noted in the Huskvarna and Jönköping areas. An 
investigation revealed that workers at the Huskvarna factory were affected to a 
large extent. Eventually, evidence was presented that pointed to the popular 
analgesic mixture “Dr Hjorton’s headache powder” as the causative agent.[165] 
The powder contained a mixture of phenacetin, caffeine and phenazone. It was 
sold over the counter (OTC) and had reached a large popularity in the specific 
area. Phenacetin also had other side-effects, such as methemoglobinemia, anemia, 
and uroepithelial cancer[166, 167] and soon was banned in Sweden, followed by 
other countries. The renal damage caused by phenactein was named “analgesic 
nephropathy”.  
 
Later, in the 1980’s, when it was noted that the incidence and prevalence of 
analgesic nephropathy did not decline as expected after the removal of phenacetin 
from the market, other types of analgesic drugs regained attention as causes of 
CKD.[168] In experiments, phenacetin alone had not demonstrated the expected 
toxic effects. It was the major metabolite, acetaminophen (paracetamol) that was 
accumulated in the renal papillae. Acetaminophen was suggested to increase free 
radical formation and thereby induce cell death. Aspirin, which also was a 
common compound in the analgesic mixtures, produced acute nephrotoxic effects 
and was suspected to contribute to renal damage.[168, 169] The term “analgesic-
associated-nephropathy” was then introduced to refer to the possible negative 
effects by different types of analgesics on the progression and development of 
CKD. 
 
One theory was that analgesic nephropathy was caused by the abuse of analgesic 
mixtures containing two or more analgesic substances plus caffeine. 
This was later suggested by an expert ad-hoc committee of the National Kidney 
Foundation in 1996.[170] The mechanism behind the additive effect of analgesic 
mixtures was attributed to that aspirin caused reduced glutathione depletion of 
the tubular cells, hereby enhancing the acetaminophen-induced nephrotoxic effect 
by of reactive oxygen species formation. [171]Although some support was 
presented for this theory,[172-174] a peer-review in 2000 concluded that there 
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was not enough evidence for the association between analgesic mixtures and 
CKD.[175] Later, it was shown that the decrease in analgesic nephropathy was 
similar in both Australia and Belgium despite the fact that analgesic mixtures had 
overtaken the market in Belgium whereas in Australia single-substance drugs 
were used.[176] The Australian study showed that the incidence was actually 
decreasing and that the increased prevalence was caused by a greater number of 
older patients in dialysis. A recent autopsy study demonstrated that the 
morphological and pathological features of analgesic nephropathy has 




When phenacetin disappeared from the market, acetaminophen largely took its 
place as the most popular analgesic substance. Acetaminophen was first used as 
an analgesic drug already in 1893, but was not introduced to the US market until 
1950 and in Australia in 1956.[178] The antipyretic action of acetaminophen is 
due to central inhibition of prostaglandins, but the analgesic effects are probably 
due to both central and peripheral actions.[179] Today, acetaminophen is the 
most sold OTC analgesic in Sweden with more than 40 Defined Daily Doses per 
1000 inhabitants. [180] 
Several epidemiological studies have investigated the relationship between 
acetaminophen and CKD. In almost every case-control study,[181-185] but not 
all, [186, 187]acetaminophen use was associated with a greater risk of developing 
either CKD or ESRD. Many of the earlier studies had problems due to residual 
confounding from phenacetin,[183, 184, 188-190] which was still in use in some 
countries. Other problems were methodological shortcomings such as recall bias, 
and most important prothopatic bias.[191] The cases in the studies had been 
selected late in their course of disease and analgesic use due to early symptoms 
from the renal disease itself or the primary cause (e.g. diabetes, rheumatoid 
arthritis), may have inflated the analgesic-CKD relationship. Patients late in the 
course of the disease may also have been advised to change their use of analgesic 
from aspirin or non-steroidal anti-inflammatory drugs, which are known to have 
acute effects in the kidneys, to acetaminophen. In a case-control study from our 
own research group, Fored et al found an association (OR 2.5, 95% CI 1.7-3.6) 
between acetaminophen regular use and risk of CKD, which was still present 
after the exclusion of analgesic use the closest 10 years before inclusion. [185]  
 
Not many follow-up studies have analyzed the risk of declining renal function 
attributed to analgesic drugs without phenacetin. One large study in the US 
followed 4494 apparently healthy men over 14 years.[192] Analgesic use was 
assessed retrospectively by a questionnaire. There was no association between 
acetaminophen use (OR 1.02, 95% CI 0.55-1.90 among heavy users [>2500 pills] 
compared to never users) with >30 ml/min/1.73 m2 decline in estimated GFR. 
However, in another study of 1697 healthy women there was a significant 
association between acetaminophen use and >30 ml/min/1.73 m2 decline in GFR 
between 1989 and 2000 (OR 2.04, 95% CI 1.28-3.24). The OR increased with 
lifetime cumulative acetaminophen use. Analgesic use was registered 
retrospectively in 1999.[193] 
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2.5.2 Aspirin 
 
The association between aspirin (acetylsalicylic acid) and CKD was explored due 
to the acute toxic effects seen when large doses of aspirin were administered in 
experimental trials[194, 195]. Aspirin, as well as non-steroidal anti inflammatory 
drugs act mainly through inhibition of prostaglandin synthesis, which is essential 
to regulate the renal blood flow[196]. Despite this, the overall epidemiological 
evidence of aspirin as a cause of CKD is weak[197].  
The case-control studies showing an increased risk of CKD with aspirin use are 
few.[185, 187, 189] In the case-control study by Fored et al regular use of aspirin 
had ha significant association to CKD (OR 2.5, 95% CI 1.9-3.3). The association 
was strongest among subjects with diabetic nephropathy (OR 2.9, 95% CI 1.9-
4.5). However, the association failed to remain significant after the exclusion of 
aspirin use 10 years prior to inclusion.[185] 
 
In the two longitudinal studies on healthy men and women there was no 
relationship between aspirin use and reduction in GFR.[192, 193] In fact, both 
studies presented OR’s below one for this association, although non-significant. 




2.6 LEAD METAL EXPOSURE AND CKD 
 
2.6.1 General lead toxicity 
 
The heavy metal lead is a ubiquitous pollutant. It enters the body through 
ingestion or inhalation. The main source of environmental lead is from ingestion 
of contaminated food items and dust containing lead, secondary to lead emission 
into the atmosphere from smelters, incinerators and leaded gasoline.[198] 
Inhalation of lead in air may also contribute, especially if air concentrations of 
lead are high, for example during occupational exposure. Ambient air exposure to 
lead has decreased during the last decades mainly because of legislative actions 
aiming at removing lead in petrol. Blood lead levels has also decreased among 
workers occupationally exposed to lead.[199] Data from the NHANES study in 
the United States show a decline in the geometric mean blood lead (PbB) level in 
the general population from 13.1µg/dL in 1976-1988 to 1.6µg/dL in 1999-
2002.[200, 201] Likewise, the average PbB concentration in the Swedish 
population has decreased considerably since the 1980’s.[202] 
 
Lead intoxication mainly gives rise to anemia, polyneuropathy, encephalopathy, 
and gastrointestinal symptoms. It is stored in the body in bone, and released 
during periods of increased bone turnover. The half-life in blood and soft tissues 
is about 30 days while the half-life in bone is 4-20 years.[203] Because of the 
short mean biological life in blood, PbB primarily reflects on-going exposure. 
However, if exposure to lead has been for long periods, giving rise to a high body 
burden of lead, PbB will remain elevated for extended periods.[204] To measure 
the accumulated lead (lead burden) one can perform a mobilization test using a 
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chelating agent. This is done by intramuscular or intravenous administration of 
CaNa2 ethylene-diamine-tetraacetic acid (EDTA).[205] 
 
2.6.2 Lead exposure and risk for CKD 
 
In 1929 Nye first described a high incidence of young people with chronic 
nephritis in Queensland, Australia and linked it to the high frequency of 
childhood lead intoxication in the same area.[206] In later follow-up studies the 
children treated for lead intoxication showed a much higher age-adjusted 
mortality rate caused by chronic nephritis compared to the general 
population.[207, 208] Classical lead nephropathy, exhibited at toxic levels, is 
described to cause minimal proteinuria, a benign urinary sediment, 
hyperuricemia, and often hypertension. The kidneys are described as granular and 
contracted. Renal biopsies show tubular atrophy and interstitial fibrosis without 
cellular infiltration. The glomeruli are sclerotic and the arterioles often show 
intima proliferation and hyaline degeneration of the media. In the proximal 
tubules, acid-fast nuclear inclusion bodies, consisting of a lead-protein binding 
complex, can be seen.[209] (Figure 2) Increased urinary secretion of N-acetyl-β-
D-glucosaminidase (NAG), lysozyme, and urinary α-1-microglobulin can be 
observed early among lead-exposed individuals.[210, 211] 
 
2.6.2.1 Epidemiological studies 
 
Occupational studies investigating lead exposure have been cross-sectional with 
few exceptions. In spite of all that has been reported on effects from acute or 
ongoing excessive exposure, there are only a few occupational studies where the 
GFR is significantly reduced.[212-214] Longitudinal studies provide no further 
evidence of lead causing CKD. The largest longitudinal study on 537 lead 
workers over 2.1 years showed no general effect of PbB (mean baseline 31.3 
µg/dL) on creatinine clearance.[215] Mean creatinine clearance increased during 
the study period. In another longitudinal study of 30 lead workers over 10 years 
higher PbB at baseline was associated with a subsequent decrease in S-Cr, 
suggesting hyper filtration.[216] 
 
During recent decades several epidemiological studies have presented suggestive 
evidence that low levels of environmental lead cause kidney disease in large 
proportions of the general population.[200, 217] It has also been suggested that 
low levels of environmental lead exposure contribute to increased cardiovascular 
mortality and high blood pressure.[218, 219] Most of the general population 
studies are also cross-sectional. The majority of the studies with renal function 
outcomes use S-Cr or creatinine clearance, whereas some studies use Cystatin 
C.[220, 221]  Although most of these studies showed an association between 
higher PbB and lower creatinine clearance or estimated GFR,[201, 217, 218, 220, 
222] two studies (of which one was on children) instead presented an inverse 
correlation,[223, 224] one found an association only among hypertensives, 
[200]and the other lacked any association.[225]  
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Only three case-control studies investigating lead exposure and its association 
with CKD are published. One study measuring lead by the expert rating method 
found that the odds ratio (OR) for CKD associated with lead exposure was 2.1 
(95% CI 1.2-4.4).[226] Another similar case-control study found no such 
association.[183] In a small study, 55 patients with end-stage renal disease had 
significantly higher PbB compared to 53 age and sex-matched controls whereas 
mean tibia lead did not differ significantly.[227] The OR for end-stage renal 
disease associated with tibia lead ≥20 µg/g was 1.6 (95% CI 0.6, 4.4) and thus 
showed a non-significant positive association.  
 
2.6.2.2 Experimental studies 
 
Animal studies evaluating lead exposure and renal function present similar results 
compared with the occupational reports in showing tubular effects and nuclear 
inclusion bodies, and to some extent glomerular hyper filtration.[228, 229] Rats 
fed with high doses of lead (mean PbB 125 µg/dL) increased their GFR at 3 
months compared to control rats, but had lower GFR at 6 and 12 months.[230] 
The kidneys had proximal tubule inclusion bodies, interstitial fibrosis, tubular 
atrophy, and focal glomerular sclerosis. Rats fed with lower doses of lead (mean 
PbB 29 µg/dL) presented with glomerular hyper filtration and increased NAG 
secretion after 3 months, but after 12 months the renal biopsies showed almost no 
morphological changes. Chelate treatment improved GFR both among lead-fed 
rats and control rats.[231, 232] 
 
 
Figure 2. Normal renal tubular cell to the right. On the left-hand side 























To define risk factors for start of renal replacement therapy and for death among 
unselected patients with severe chronic kidney disease 
 
To define risk factors for decline in estimated glomerular filtration rate among 
patients with severe chronic kidney disease 
 
To establish to what extent analgesic drug use affects decline in glomerular 
filtration rate among patients with chronic kidney disease 
 
To determine to what extent occupational lead exposure is a risk factor for 
chronic kidney disease development, or increase in decline of glomerular 
filtration rate among patients with established chronic kidney disease 
 
To establish how “timing of dialysis initiation” is associated with mortality in 
patients with chronic kidney disease 
 
While performing these studies, to learn more about epidemiological methods 
 






The study took place in Sweden where an important characteristic of the 
community is the use of personal identification numbers. A unique personal 
identification number is assigned to every Swedish citizen at birth or immigration 
and is consistent through all governmental systems, such as the tax registry, 
population registry, health care, and the school system. This enabled us to 
identify the study base, which consisted of all Swedish-born citizens living in 
Sweden between May 20 1996 and May 31 1998 (n=5.3 million).  
 
Another characteristic of Sweden is that health care is administered by a county 
council, “Landstinget”, which primarily is funded by taxes. The fees paid at each 
visit are low and affordable by most citizens. Above a certain low level health 
care and prescribed drugs are free of charge. Privately financed health care 
initiatives were few when the study began, but have become more common since 
2000. Private health care insurances are very rare in Sweden and all costs for 
RRT are covered by the county council in which the patient resides. The result is 
that access and quality of health care are relatively equal and not related to socio-
economic status or place of residence.[233]  
 
4.2 STUDY SUBJECTS 
 
Individuals, 18-74 years old, born and living in Sweden during the inclusion 
period (May 20 1996 and May 31 1998) were eligible. The case-selection was 
founded on individuals who had a blood sample of S-Cr which for the first time 
exceeded a predefined limit. The limit was 300µmol/l (3.4 mg/dL) for men and 
250µmol/l (2.8 mg/dL) for women. Women have less muscle mass than men. 
Thus, the S-Cr is lower in women for the same corresponding eGFR (19 and 17 
ml/min/1.73 m2 for men and women respectively at our inclusion limit). The 
reason for the S-Cr elevation had to be CKD. Since the definition of CKD 
includes a time aspect, a second S-Cr test was taken after three months on those 
individuals who had not yet started RRT. To allow fluctuation of the values and 
regression towards the mean the second S-Cr limit was lower, 250µmol/l (2.8 
mg/dL) for men and 200µmol/l (2.3 mg/dL) for women.  
 
To ensure a complete case-finding structure, the chemical laboratories in Sweden 
(n=69) produced monthly lists of elevated S-Cr values. More than 10,000 values 
were evaluated by Fored, Ejerblad et al in the original case-control study.[185] 
The CKD diagnosis was performed by the collaborating nephrologists (n=60) at 
the hospital were the blood sample was taken through review of the patient’s 
medical record. Post-renal obstruction, pre-renal volume depletion, septicemia, 
previous kidney transplantation, and terminal illnesses (malignances) were 
conditions that excluded the individual from further participation. The primary 
renal disease diagnosis was otherwise founded on ordinary clinical follow-up and 
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kidney biopsy, if necessary. The nephrologists also asked the patients about their 
final participation and informed consent. 
 
Control subjects were selected from the study base of native Swedes 18-74 years 
old, using the national “registry of the total population”. This registry is 
controlled by the Swedish Tax authority and continuously up-dated. On three 
occasions during the study inclusion period control subjects, frequency-matched 
for age (in 10-year strata) and sex, were randomly selected. Control subjects 
provided informed consent before enrolment. 
 
4.3 EXPOSURE ASSESSMENT 
 
After the decision of final eligibility the patients and the control subjects were 
mailed a questionnaire with a wide range of questions on anthropometric data, 
diet, smoking habits, and alcohol use. Thereafter, they were interviewed fact-to-
face by professional interviewers from Statistics Sweden, a government agency 
responsible for producing official statistics. The interviewers were not aware of 
the study hypothesis, but we were unable to blind them from case and control 
status. The interviewers had computers to help them interview the subjects in a 
standardized manner. The questions covered medical history, medical drug use, 
occupational history and work-related exposures.  
 
4.3.1 ANALGESIC USE 
 
A life-long history of non-narcotic drug use was obtained. Both prescribed and 
non-prescribed drug use was recorded. During the interview the study subjects 
were shown a booklet with pictures of present and historical packages of non-
narcotic analgesic drugs to help them remember earlier use. There were pictures 
of all analgesic drugs on the market since 1960 containing phenactein or 
acetaminophen and 78 pictures of the most sold other non-narcotic drugs. If a 
participant had used more than 20 pills of a certain type of drug, detailed 
questions followed to verify the frequency and dosage of tablets used during the 
participant’s lifetime. Likewise, if the participant reported regular use, questions 
followed to investigate the dosage, frequency of use, and age of the subject when 
regular use began and discontinued. Lifetime cumulative dose was calculated for 
each substance knowing the amount each brand contained and given the subject’s 
self-reported use.  
 
We defined regular users as users of more than two tablets a week, for more than 
three months at the time of inclusion. Lifetime cumulative dose was divided into 
categories of non-users, 1-99 gram (g), 100-499g, 500-2999g, and ≥3000g. Non-
users were defined as a lifetime cumulative use of less than 20 tablets. Analgesic 
use during follow-up was based on information in the medical records. If a 
subject had received at least one prescription of analgesics or if it was recorded 
on the drug list in the record, he/she was defined as a user. Patients prescribed 
low-dose aspirin, either self-reported or indicated in the medical record were 
considered regular users in all the follow-up analyses. 
 
   23 
4.3.2 LEAD EXPOSURE 
 
During the interview, all participants provided a complete life-time history of 
their occupations. This history included company name, occupational title, work 
tasks and duration of each employment period of at least one year. The answers 
were then evaluated by industrial hygienists knowledgeable about common 
exposures associated with different occupations. Participants at risk of work-
related exposure were then subjected to a telephone interview. During that 
interview questions were asked on frequency and duration of the 
exposure/exposures, and about personal protective equipment and ventilation. 
Although the hygienists were unaware of the study hypothesis, it was impossible 
to blind them from case and control status since the cases sometimes revealed 
they had kidney disease. 
 
The intensity of lead exposure was judged to be low, moderate or high for each 
employment period. The method used is the “expert rating method”.[234-236] 
Low lead exposure intensity was 3-10% of the Occupational Exposure Limit 
([OEL] defined by the Swedish Work Environment Authority in 1996 as 0.1 
mg/m3) moderate exposure was 10-30% of the OEL, and high exposure was 
>30% of the OEL. No exposure was defined as exposure below 3% of the OEL. 
In the analyses, we estimated a low intensity to 0.0067 mg/m3, medium exposure 
0.02 mg/m3, and high exposure 0.075 mg/m3 (75% of the OEL). The average 
level of lead exposure was calculated as the time-weighted average of the 
estimated OEL x proportion of workdays exposed during a subject’s lifetime 
occupational history until inclusion in the study. Only employments with 
exposure to lead were included. Lifetime cumulative lead exposure was computed 
as the average lead exposure x duration. Categorization was made according to 
tertiles among exposed controls. 
 
 
4.4 OUTCOME MEASURES AND FOLLOW-UP 
 
4.4.1 Register data 
 
At the beginning of year 2003 we asked the cases (CKD cohort) if they agreed to 
take part in the follow-up study. We then used the personal identification number 
and linked it to the National Population Register, the Swedish Causes of Death 
Register, and the Swedish Renal Registry (SRR, Svenskt Njur Register). The 
National Population Register is kept by the Swedish Tax Authority since 1991 
when they took over from the Swedish State church. The population register 
holds information about the birth date, birth location, current residence, and dates 
of emigration/immigration. The accuracy of the registry is very good. Only 0.1% 
of the population is “over covered”, i.e. registered but not living in Sweden.[237] 
The problem with “over coverage” is greater among immigrants.  The cause of 
death register is kept by the Swedish National Board of Health and Welfare, and 
is continuously up-dated. It currently lags 18 months at the most. The number of 
unreported causes of deaths are <1%. The coding error is approximately 0.3%. 
[238]The Swedish Causes of Death Register was founded in its current form in 
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1952, although the history stretches as far back as 1749. The primary cause of 
death and contributing causes are registered according to the International 
Classification of Diseases (ICD) 10th version. The Swedish Renal Registry is a 
registry for health care quality assessment, run by the health care providers and at 
the time of the study located in Skövde. It was founded in 1994 and covers about 
95% of the dialysis patients in Sweden after 1997.[6] This register contains data 
on timing of renal replacement therapy, type of therapy (hemodialysis, peritoneal 
dialysis and kidney transplantation), and primary renal diagnosis. We performed 
two linkages to the registries; one in 2003 (Study I), and one in 2007 (Study II, 
III, IV).  
 
4.4.2 Information from medical records 
 
To be able to estimate the decline in glomerular filtration rate (progression rate) 
we recorded up to six S-Cr values for each patient during the period from 
inclusion to either start of RRT, death, or June 1 2003. The S-Cr values were 
found through visual inspection of the patient’s medical record. The blood 
samples were taken during the routine clinical follow up of the patient. With 
previous knowledge of the timing of RRT start and death date we divided the 
follow-up time (whichever came first of RRT start, death or June 1 2003 minus 
inclusion date) into five equal time intervals. Four dates, apart from inclusion 
date and end-of-follow up date, were then suggested. We registered values from 
the records that were closest to the suggested date. In addition to S-Cr, we 
abstracted information on blood pressure, weight at end of follow up, and 
prescribed drugs. We only registered prescribed and non-prescribed drugs at 
inclusion and during the follow up period. During the follow up, utilization for 
more than three months (one prescription) was considered to be “use” whereas 
less than three months was considered “non-use”.  
 
4.4.3 Categorization of covariates 
 
In all the analyses age at inclusion was divided into predefined categories (<45, 
45-64, ≥65 years) while body mass index (BMI) was categorized as proposed by 
the World Health Organization (<20, 20-24.9, 25-29.9, ≥30 kg/m2). Estimated 
glomerular filtration rate, plasma albumin, hemoglobin, and mean arterial blood 
pressure at inclusion were categorized into quartiles. Smoking (lifetime 
cumulative pack-years) and alcohol use (gram/week) was divided into three 
groups; non-users, and below and above the median value among users. Self-
reported level of education was categorized into predefined groups (≤9 years, 10-
12 years, ≥13 years) corresponding to the different levels in the Swedish school 
system (elementary school, high school, and university). Proteinuria was 
categorized as either high or low, according to the first registered value at 
inclusion. High was defined as a value above 1500 mg total proteinuria/24 hours 
or above 1000 mg total albuminuria/24 hours or a dipstick quantitative value 
exceeding one. The primary renal disease diagnosis was assigned by the clinical 
nephrologists at inclusion and first categorized into systemic diseases, 
glomerulonephritis, interstitial nephritis, diabetic kidney disease, hereditary 
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diseases, hypertensive kidney disease, other renal diseases and unknown diseases 
(Paper I)   
Later, these diagnostic groups were merged into diabetic kidney disease, 
glomerulonephritis, hypertensive kidney disease (nephrosclerosis), and other 
diseases (Paper II-IV). 
 
4.4.4 Co-morbidity Index 
 
From the medical records we recorded information on co-morbid diseases at 
inclusion (previous myocardial infarction, previous cerebrovascular lesion, 
peripheral arterial disease, congestive heart failure, ischemic heart disease, 
chronic obstructive pulmonary disease, hemiplegia, dementia, mild or moderately 
severe liver disease, diabetes with and without complications, metastatic cancer, 
solid tumor disease or leukemia, systemic inflammatory disease, and AIDS). The 
definition of a co-morbid condition was that it was diagnosed in the record. We 
used the comorbid conditions to calculate the Charlson co-morbidity index (CCI). 
CCI is the most frequently used and validated co-morbidity index in follow-up 
studies,[239] including studies of patients with end-stage renal disease.[240] CCI 
assigns a weight between 1 and 4 to each co-morbid condition. The sum of all 
weights comprises the index score. Chronic kidney disease has a score of 2, and 
thus 2 is the lowest score possible for a patient in the cohort. We categorized CCI 
in approximate tertiles (score 2, 3-4, >4).  
 
4.5 STATISTICAL ANALYSIS 
 
In the studies we used statistical analysis software (SAS) version 9 or higher 
(SAS Institute, Inc, Cary, NC, USA) (Study I) and STATA version 9 or higher 
(StataCorp LP, www.stata.com) (Study II-IV). In all the analysis of progression 
rate we defined end of follow-up to June 1, 2003 since we did not abstract 
medical record information beyond that date while we used later dates in some of 
the Cox proportional hazards regression models.  
 
4.5.1 Analysis of the natural history (I) 
 
Descriptive statistics was performed to characterize the study population and 
their renal diseases. Patients were followed from the date of inclusion (the date of 
the first S-Cr elevation) through the date of the outcome of interest (death or 
RRT onset) or the end of the study period (December 31, 2002), whichever came 
first. Cox proportional hazards regression models were used to explore the 
relationship between the independent variables under study (age, sex, BMI, 
primary renal disease, estimated GFR, transplanted during follow-up [only in 
mortality analysis]) and the outcomes of interest, RRT and death. Estimated GFR 
was calculated both with Cockcroft-Gault formula and the 4-variable MDRD 
equation. Only results using the MDRD equation are presented in this paper. 
Crude and adjusted relative rates (RR) and 95% Confidence Intervals (CI) were 
computed for each of the outcome variables, RRT and death. Mortality data were 
directly standardized against age and sex-specific all-cause mortality for Sweden 
by inclusion year (1996-1998).  
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4.5.2 Analysis of analgesics (II) 
 
Summary statistics described the mean, median and range for the follow-up 
information (number of days, number of measurements) and eGFR at inclusion. 
Baseline characteristics were stratified by the main exposures (acetaminophen 
and aspirin). Proportions (categorical variables) and means (continuous variables) 
were produced and stratified by both regular use and lifetime dose of 
acetaminophen and aspirin.  Parametric (t-test and chi-square) and non-
parametric tests (Kruskall-Wallis) assessed statistical differences between 
groups. In the analyses of progression rates, we excluded individuals with less 
than 14 days of follow-up or those who lacked a second S-Cr estimation. To 
characterize the change in estimated GFR we first described the individual-
specific trend by fitting a linear regression model for each individual estimating 
the beta coefficient (slope), which represents the rate of change in eGFR per year. 
The decline in eGFR was assumed to occur at a constant rate (linearly) which is 
the most common way to describe renal deterioration in the scientific 
literature.[36, 50] The estimated beta coefficients’ distribution was summarized 
using both mean and median, and stratified by analgesic use and all other 
variables of interest. Patients with follow-up shorter than one year had their 
progression rate multiplied and presented by year to be comparable with the 
others in the univariate analysis.   
 
In the further analyses, both the correlation among repeated measurements and 
the unbalanced data were handled in a linear mixed effects model, with both 
fixed and random intercept and slope. For each exposure of interest (regular use 
versus no regular use at inclusion and lifetime cumulative dose), the fitted model 
included the exposure and the linear time effects, sex and age at baseline. The 
study hypothesis was tested by adding appropriate interaction terms between the 
exposure and time of follow-up. Statistically significant or biologically relevant 
variables were left in the final model (age, sex, angiotensin converting enzyme 
inhibitor or angiotensin II receptor blocker use, and mean arterial pressure). The 
goodness of fit in the final model was assessed through visual inspection of the 
observed and fitted trajectories and study of the estimated standardized residuals. 
All the fitted models reproduced the observed trends, and the residual plots did 
not reveal any substantial deviation from the underlying assumptions. In the 
analysis of renal survival we used a Cox proportional hazard model, including the 
same confounding variables as in the mixed model. In addition, we included co-
morbidity and primary renal disease. Patients were censored at the date of RRT 
onset or the date of death, whichever occurred first.  
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4.5.3 Analysis of occupational lead (III) 
 
In addition to the above-mentioned covariates, we included self-reported 
information on ever diagnosed with gout, diabetes, or hypertension. We first 
compared cases and controls in univariate analyses using chi-square statistics 
(Fisher exact) for categorical variables and t-tests (normal distribution) or 
Kruskall-Wallis non-parametric tests (non-normal distribution) for continuous 
variables. We then produced age- and sex-adjusted Odds Ratios (OR) for CKD 
overall among ever lead exposed as well as in relation to average and life-time 
cumulative lead exposure using logistic regression modeling with non-exposed as 
the reference category. In sub-analyses, we also estimated the ORs for CKD due 
to each of the largest groups of primary renal diseases; glomerulonephritis, 
nephrosclerosis, and diabetic nephropathy. In the multivariate logistic regression 
model we first included all risk factors known to be associated with CKD and 
those that attained a p-value below 0.25 in the univariate analyses. Variables that 
changed the coefficient for the main exposure of interest by more than 10% were 
retained in the final model, which also included risk factors known a priori to be 
associated with CKD. The Goodness of fit was assessed by the Hosmer-
Lemeshow test. 
 
 In the analysis of the follow-up data we estimated the individual progression rate 
along the disease trajectory using up to six S-Cr values and assuming a linear 
trend (see section 4.5.2). In the multivariate analysis we handled both the 
correlation among repeated measurements and the unbalanced data in a linear 
mixed effects model, with both fixed and random intercept and slope.[241] The 
fitted model included the exposure and the linear time effects. The study 
hypothesis was tested by adding appropriate interaction terms between the 
exposure and time of follow-up. Significant variables and potential confounders 
were retained in the final model.  In addition, we also examined renal survival in 
relation to previous lead exposure using a Cox proportional hazards model. In 
this analysis it was possible to extend the follow-up time to Dec 31 2005 because 
of complete registry data. Patients were censored at start of RRT, at death before 
RRT, or end of follow-up whichever occurred first. The selection of the adjusting 
variables followed the same principles as in the logistic and linear regression.  
 
4.5.4 Analysis of early versus late dialysis (IV) 
 
For each patient we aimed at estimating GFR (from S-Cr) at least six times along 
the disease trajectory during follow-up. The 4-variable MDRD equation was used 
to estimate the GFR.[28] Since the S-Cr determinations were part of routine care, 
they varied in number and timing. The distribution of S-Cr values along follow-
up was highly unbalanced. We estimated the individual progression rate by fitting 
a linear mixed effects model, with both fixed and random intercept and 
slope.[241] If we could not calculate an individual progression rate (if the patient 
had only a first eGFR value) the model imputed an estimate based upon similar 
patients in the total cohort.   
 28 
4.5.4.1 Classification of early and late dialysis 
 
The timing of dialysis start was defined in terms of attained eGFR value. We 
used the last value before initiation to decide whether timing was early or late. 
However, if the latest S-Cr determination was more than 30 days before initiation 
of dialysis we inferred the last eGFR value by using the last recorded eGFR and 
the individual progression rate of the patient according to the principle “last value 
carried forward”. Patients were censored at the date of the latest eGFR recording 
if it was >2 years before end of follow-up. To be consistent with other studies, 
[153, 155] we defined early and late initiation as dialysis start with an eGFR ≥7.5 
and <7.5ml/min/1.73 m2, respectively. To allocate deaths or other censoring in 
patients without dialysis treatment to the correct eGFR stratum, we used the S-Cr 
closest to these events and otherwise followed the same principles as the 
allocation to early versus late dialysis start.  
 
The individual progression curves were used to establish when patients moved 
between the predefined strata of eGFR. We classified a patient not yet subjected 
to dialysis with an eGFR 20 -7.5ml/min/1.73 m2 as a “candidate for early 
dialysis”. When eGFR fell below 7.5ml/min/1.73 m2, the patient was moved to 
the “candidate for late dialysis” category. Patients who later improved and 
permanently regained an eGFR value of >20ml/min/1.73 m2 were regarded as not 
being at risk for dialysis and did not contribute with person-time thereafter. 
 
4.5.4.2 Analysis of mortality in early and late start dialysis 
 
The study covariates were summarized with proportions and means stratified 
according to the last eGFR-status (early versus late). Differences between the 
groups were assessed by non-parametric (Kruskall-Wallis for continuous, Chi-
Square for categorical variables) statistics. The variables were then studied 
according to their possible effect on the exposure early or late start of dialysis. 
Patients’ survival time (in days) to dialysis was censored when they either died or 
reached the end of the study (June 1, 2003) alive without having started the 
treatment. Patients who received a renal transplant were censored at 
transplantation date. Patients with a pre-emptive renal transplantation were 
directly censored at transplantation date and did not contribute to the survival 
analysis of early and late dialysis mortality. 
 
We fitted a time-dependent multivariate proportional hazards regression (Cox) 
model that included the survival time in all of the different strata (candidate for 
early dialysis, candidate for late dialysis, subject to early start dialysis, and 
subject to late start dialysis) and adjusted for the other covariates including eGFR 
at inclusion (as a continuous variable) and progression rate (rate of change of 
eGFR per year) divided into quartiles. Thus, most patients started generating 
person-time at the point in time when eGFR was observed or projected to be 20 
ml/min/1.73 m2, and were transferred to the “candidate for late dialysis” when 
eGFR passed 7.5 ml/min/1.73 m2. The final model included variables 
significantly associated with the outcome as well as a priori suspected 
confounding factors, while the variables plasma albumin, hemoglobin, mean 
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arterial pressure, and proteinuria at inclusion were dropped due to trivial effects 
on the associations of interest. The proportionality assumptions, checked through 
visual inspection of the log of the incidence rates were satisfactorily met.  
 
4.5.4.3 Analysis of mortality before and after start of dialysis 
 
Kaplan Meier curves described the survival among patients, still without RRT. 
The patients were divided into four strata (eGFR ≥15, 10-14.9, 7.5-9.9, and <7.5 
ml/min/1.73 m2) according to the actual dates of the recorded S-Cr values. 
Patients who moved from one eGFR stratum to another were censored in the old 
stratum and re-started from time 0 in the new. Definite censoring occurred at 
initiation of RRT. We further produced a Kaplan Meier survival curve without 
stratification for eGFR level and compared it to a corresponding curve for 
patients after having started dialysis, starting on the day of dialysis initiation. 
Censoring occurred when a patient got a renal transplant. We also fitted a time-
dependent Cox model where we started follow-up registration when eGFR passed 
15 ml/min/1.73m2 and with dialysis as a dichotomous no/yes variable. The 







5.1 BASELINE CHARACTERISTICS 
 
Between the years 1996 and 1998, 1189 eligible patients were identified; 69 
patients died shortly after diagnosis, 83 were too ill to be interviewed, and 111 
refused to participate. Of the remaining 1120 patients 926 (83%) agreed to 
participate in the case-control study. Out of 1330 population controls, 998 (75%) 
participated (221 declined, 56 could not be reached, and 55 were too ill to be 
interviewed). In the follow-up study another 6 patients declined to participate and 
thus 920 were included. The age and sex distribution is presented in Table 2. As 
expected from the frequency matching, there was no difference in age and sex 
among the cases and controls. There were more men than women. 
Mean age was 58.0 years for men and 56.8 years for women. 
 






Age (mean)(SD) 57.6 (13.6) 57.6 (13.5) 
   
Sex (n)   
Men (%) 597 (64.5) 653 (65.4) 
Women (%) 329 (35.5) 345 (34.6) 
 
 
The median serum creatinine among the patients was 336µmol/l among men and 
281µmol/l among women. The overall mean estimated creatinine clearance using 
Cockcroft-Gault formula was 21.1ml/min (SD 7.3), range 2.2 – 53.0 at inclusion. 
The mean estimated creatinine clearance was 22.3ml/min for men (range 2.2 – 
53.0) and 19.2 ml/min for women (3.4- 34.7). Using the 4-variable MDRD 
equation (1999) the mean estimated GFR (eGFR) was 16.5ml/min/1.73 m2 (range 
1.7-31.34) for men and 15.4ml/min/1.73 m2 (range 2.4 – 27.4) for women.   
 
5.1.1 Primary renal diseases among patients 
 
The most common renal diagnose was diabetic nephropathy, followed by 
glomerulonephritis, and nephrosclerosis (Table 3). About 30% of the renal 
diagnoses were founded on renal biopsies. Among patients with 
glomerulonephritis as many as 61% (n=135) had performed a biopsy. Most of the 
patients (n=798) had known renal disease before they were included in the study, 
while 120 patients reported that they were not diagnosed before study inclusion. 
Most of these previously unknown patients had diabetic nephropathy (42%) or 
nephrosclerosis (20%).  
 
   31 
Table 3. Renal diseases among the patients  
 
Primary renal disease Number Percent (%) 
Systemic disease 81 8.8 
Glomerulonephritis 220 23.9 
Interstitial nephritis 28 3.0 
Diabetes 284 30.9 
Hereditary disease 98 10.7 
Nephrosclerosis 138 15.0 
Other renal diseases 27 2.9 
Unknown 44 4.8 
 
 
5.1.2 Baseline covariates among the patients  
 
The covariates at the beginning of follow-up are presented in Table 4. Most of 
the 920 patients (58%) with CKD had ≤9 years of education, whereas a smaller 
proportion (18%) had attended university. Twenty-five percent were non-users of 
alcohol and 40% had never smoked. There were significantly fewer smokers, and 
more alcohol users among patients in the highest educational level. Mean BMI at 
inclusion was 25 kg/m2, range 15.4-49.2 kg/m2. There were 13.7% obese (BMI 
>30 kg/m2) patients at beginning of follow-up, while 34.5% were overweight 
(BMI 25-30 kg/m2).  
 
Although 38.4% of the patients lacked any anti-hypertensive medication, 23.3% 
were on two different drugs, and 6.6% were on three. Beta blockers and calcium 
channel antagonists were the most prescribed antihypertensive drugs (33.6 and 
33.9% respectively), whereas ACE/ARB were less common; only about 30% 
were on any of those substances. However, 40.5% of the diabetic patients were 
prescribed ACE/ARB, probably reflecting the prescription pattern among 
nephrologists in Sweden during the 1990’s. The use of ACE/ARB was also 
significantly associated with educational level. Patients in the highest educational 
level were prescribed ACE/ARB to a larger extent compared to patients with the 
lowest educational level (40.4% versus 25.3%). The mean arterial blood pressure 
at inclusion was however similar across educational level, BMI strata, age 
categories and gender. Patients prescribed more antihypertensive drugs had 
significantly higher blood pressure; the mean arterial blood pressure among 
patients with no anti hypertensive drugs was 120 mmHg (SD 18.3) compared to 
126.4 mmHG (SD 21.1) among those prescribed three medications.  
  
Plasma albumin at the beginning of follow-up was correlated to both BMI and 
eGFR; patients with lower plasma albumin tended to have lower BMI and eGFR. 
Plasma albumin was also significantly correlated to albuminuria; patients with 
<500 mg/24h had plasma albumin 36.7g/L (SD 5.8) compared to 33.9g/L (SD 
6.1) among those with >2000 mg/24h. Moreover, albuminuria was correlated to 
mean arterial pressure and smoking; subjects with more albuminuria were more 
likely to have higher blood pressure and higher lifetime cumulative smoking.  
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Education (%) ≤9 years 534 58.0 
 10-12 years 206 22.4 
 ≥13 years 168  
18.3 
 
Alcohol consumption  Non users (%) 231 25.1 
 Mean g/week among users (SD) 679 76.4 (176.6) 
    
Smoking history  Never (%) 367 39.9 
 Mean Cum pack-years among users (SD) 540 21.8 (15.9) 
    
Body Mass Index Mean kg/m2 (SD) 894 25.4 (4.5) 
    
ACE/ARB (%) Non-users  645 70.1 
 Users 275 29.9 
    
Beta blocker (%) Non-users 611 66.4 
 Users 309 33.6 
    
Calcium channel 
antagonists (%) Non-users 608 66.1 
 Users 312 33.9 
    
Number of anti 
hypertensive drugs (%) None 353      38.4 
 One 292      31.7 
 Two 214      23.3 
 Three 61       6.6 
    
Mean arterial pressure mmHg (SD) 798 110.4 (15.0) 
    
B-Hemoglobin Mean g/L (SD) 820 114.3 (17.6) 
    
P-Albumin Mean g/L (SD) 756 35.9 (6.2) 
    
Albuminuria <500 mg/24 h 111 17.8 
 500-<1000 mg/24 h 98 15.7 
 1000 - <2000 mg/24 h 130 20.8 
 ≥2000 mg/24 h 285 45.7 
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5.1.3 Co-morbid diseases 
 
We were unable to find medical records for 57 subjects. Based upon information 
in the records there were 62 (7.2%) patients with chronic pulmonary disease or 
asthma, 153 (17.8%) with coronary heart disease, 163 (18.9%) with congestive 
heart failure, 100 (11.6) with previous cerebrovascular lesion, 94 (10.9%) with 
previous myocardial infarction, 111 (12.9%) with peripheral arterial disease or 
amputation, 86 (10%) with systemic inflammatory diseases, 308 (35.8%) with 
type 1 or type 2 diabetes, 3 with hemiplegia (0.4%), 3 (0.4%) with dementia, 17 
(2%) with mild liver disease, 7 (0.8%) with severe liver disease, 67 (7.8%) with a 
solid tumor disease or leukemia, 6 with metastatic cancer (0.7%), and 51 (5.9%) 
with gastric ulcer disease.  
 
At the time of inclusion, 40.5% were diagnosed with cardiovascular disease, 42% 
men and 38% women. 86% of the patients with diabetes had diabetic 
nephropathy, whereas 3-5% of the patients with other primary renal diseases also 
had diabetes. Almost one third of the patients (31.3%) had no other disease 
diagnosed than CKD. The median CCI score was 4.0 (range 2-21). 
 
The CCI score was unrelated to eGFR at inclusion (Figure 2). It was also not 
associated with, sex, BMI, blood pressure and albuminuria at inclusion but 
positively correlated with age, alcohol consumption, and cumulative smoking. It 
was negatively correlated with plasma albumin, blood hemoglobin and years of 
education.  
 
Figure 3. Box plot of estimated glomerular filtration rate (using the 4-variable 





















































5.1.4 Analgesic drugs 
 
Eight patients did not give a complete history of analgesic use at inclusion. 
Lifetime consumption and regular analgesic use is presented in Table 5.  
 
 
Table 5.  Analgesic use at the beginning of follow-up and during follow-up 
 






 Non users 329 (36.1) - 42 (12.7) 
 ≤99 gram (g) 294 (32.2) 14 (4.8) 51(17.3) 
 100-499 g  160 (17.5) 35 (21.9) 40 (25.0) 
 500-2999 g 71 (7.8) 52 (73.2) 32 (45.0) 
 ≥3000 g 58 (3.4) 43 (74.1) 32 (55.2) 
 Missing 8 8 57 
Aspirin     
 Non users 280 (30.7) - 47 (16.8) 
 ≤99 gram (g) 289 (21.7) 63 (21.8) 72 (24.9) 
 100-499 g  212 (23.2) 89 (42.0) 88 (41.5) 
 500-2999 g 81 (8.9) 47 (51.9) 26 (32.1) 
 ≥3000 g 50 (5.5) 27 (54.0) 18 (36.0) 
 Missing 8 8 57 
1 Regular use at the beginning of follow-up 
 2 Regular use at any time during the follow-up for more than three months 
 
 
When comparing regular users of acetaminophen at inclusion with non-regular 
users, the regular users had significantly higher CCI score, lower alcohol intake, 
lower level of education, more cardiovascular disease and diabetes, and a larger 
proportion were women and regular users of aspirin. Patients with higher 
cumulative acetaminophen use were older, had lower level of education, higher 
CCI score, used ACE/ARB more frequently, smoked more, and were more often 
women. 
 
Regular users of aspirin were older, had higher CCI score, lower level of 
education, higher frequency of cardiovascular disease, diabetes and 
nephrosclerosis, and smoked more. Patients with a high lifetime cumulative dose 
of aspirin had higher CCI score and more cardiovascular disease, and used more 
alcohol per week. Most of the patients with aspirin use were users of low-dose 
aspirin (88.5%).  
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5.1.5 Occupational lead exposure 
 
Almost all participants gave a complete occupational history (n=913 patients and 
991 controls). There were 81 (8.7%) patients and 95 (9.5%) controls ever 
occupationally exposed to lead. The average lead exposure among the exposed 
was 0.016 mg/m3 (range 0.000056 – 0.075 mg/m3, standard deviation [SD] 0.023) 
while mean lifetime cumulative lead exposure was 0.21 mg*year/m3 (range 
0.000375-2.85, SD 0.42). This corresponds to lead exposure at the OEL every 
workday for approximately two years. There was no difference in the mean 
average or lifetime cumulative exposure to lead among the patients compared to 
the controls.  
 
The CKD patients smoked more than the control subjects; they had a lower 
average level of education and a higher mean BMI at 20 years of age. The 
number of subjects with gout, diabetes, and hypertension was as expected 
significantly higher among cases than among controls. Lead exposed were more 
often men, had significantly higher alcohol intake, smoked more, had lower level 
of education and were diagnosed with gout more frequently.  
Among the CKD patients who were exposed to lead there was no difference in 
the length of follow-up, number of S-Cr measurements or eGFR at inclusion 
between exposed and non-exposed, but the lead exposed had higher blood 
pressure in addition to the above mentioned differences. 
 
5.1.6 Early and late dialysis initiation 
 
At June 1 2003, 736 patients had started RRT, 90 had died before any RRT was 
initiated, and 56 were still alive and without RRT. Of the patients who started 
RRT, 28 had been given a pre-emptive renal transplantation, and so were not 
included in any of the dialysis groups, thus leaving 708 patients. There were 323 
patients who initiated dialysis early (≥7.5 ml/min/1.73m2) and 385 who initiated 
dialysis late (<7.5 ml/min/1.73m2). Mean of the observed or inferred last eGFR 
before start of dialysis was 7.6 (median 7.0, SD 3.3, range 1.8-30.1) 
ml/min/1.73m2. The mean eGFR in the early start group was 10.8ml/min/1.73m2 
(SD 3.2) and in the late start group 5.5 ml/min/1.73m2 (SD 1.2).  
 
Compared to early dialysis starters, late starters were, on average, younger, had 
higher plasma albumin and lower co-morbidity index, had less diabetes and 
cardiovascular disease, were more likely to receive a kidney transplant during the 
follow-up, and had a faster decline in eGFR per year. The patients initiating 
dialysis early were followed for 1.55 years before RRT was started compared to 
1.65 years for the late startes (p=0.5). Thus, in spite of a lower eGFR at 
inclusion, there was no statistically significant difference in time from initial 
inclusion to dialysis start among late starters compared to early starters. This was 






5.2 PROGNOSIS OF CHRONIC KIDNEY DISEASE  
 
Most of the patients included in the follow-up study started RRT. By Dec 31, 
2005, 756 patients had initiated RRT while 46 were still alive and without RRT. 
After one and three years, the proportion of patients alive and without RRT was 
64% and 29%, respectively.  
 
5.2.1 Risk factors for progressive disease (I, II) 
 
5.2.1.1 Decline in glomerular filtration rate 
 
In the analysis of progression rate we excluded 57 patients for whom we were 
unable to find medical records or a second S-Cr measurement, and another 62 
patients who either started RRT or died within 14 days from inclusion leaving 
801 patients in the analyses. Until June 1 2003, mean follow-up time was 768 
days (2.1 years) with a range of 15 to 2637 days (7.0 years). The 801 patients 
generated 4291 S-Cr observations (Figure 4). Most of the patients (68%) had a 
complete record with six measurements whereas 5% had only two. The mean 
number of S-Cr measurements was 5.2. The inter-measurement variation was 
substantial (range 2-954 days) and the data were unbalanced due to the 
differences in follow-up time. The median inter-measurement time varied from 
118 to 136 days (SD 130-146, mean 160-184 days) in the five different time 
intervals. 
 
Figure 4. Estimated glomerular filtration rate (eGFR) during at the most 7 years 
of follow-up for 801 patients, included when their serum creatinine first passed 
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With linear regression, we estimated the individual progression rate from the 
eGFR values. The distribution of the progression rates was skewed; most of the 
subjects (25th to 75th percentile) progressed between -9.7 to -2.3 ml/min/1.73 m2 
per year. The mean unadjusted decline in GFR was 9.0 ml/min/1.73 m2 per year, 
while the median decline was 5.1 ml/min/1.73 m2 per year. Patients with a very 
rapid progression rate started RRT early and thus were followed more shortly, 
whereas patients who progressed slowly and sometimes even improved were 
followed until end of follow-up. Patients with a more rapid progression rate were 
also more likely to have a higher eGFR at inclusion than patients with lower 
progression rates. The unadjusted progression rates stratified for the baseline 
covariates are shown in Table 6.  
 
In this univariate analysis, younger patients, those with higher blood pressure, 
more albuminuria, lower plasma albumin, diabetics, and men had a faster decline 
in glomerular filtration rate.  
 
Table 6.  Unadjusted decline in glomerular filtration rate per year (n=801) 
 




per year § 
Significance 
Test # 
Age (years)   <0.01 
 <45  -6.6  
 45-64  -5.6  
 ≥65  -3.8  
Sex   <0.01 
 Male  -6.0  
 Female  -4.0  
    
Estimated GFR at first 
inclusion*    
 1.7-14.8  -4.1 <0.01 
 14.8-17.2  -4.8  
 17.2-18.7  -4.9  
 18.7-31.3  -6.6  
    
Primary Renal Disease   <0.01 
 Diabetes  -6.5  
 Glomerulonephritis  -5.7  
 Nephrosclerosis -4.6  
 Other -4.7  
Co-morbidity   0.21 
 CCI <3  -5.3  
 CCI 3-4  -4.9  
 CCI >4  -5.7  
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per year § 
Significance 
Test # 
Education   0.68 
 ≤ 9 years  -4.9  
 10-12 years  -5.2  
 ≥13 years  -5.5  
Smoking   0.53 
 Never smokers  -4.7  
 ≤20 pack years  -5.1  
 > 20 pack years  -5.5  
Alcohol use   0.55 
 No use  -4.9  
 ≥32.6 grams /week -4.8  
 >32.6 grams/week  -5.5  
Body mass Index   0.68 
 <25 kg/m2  -5.2  
 ≥25 kg/m2  -5.1  
Mean arterial pressure   <0.01 
 <100 mmHg  -3.4  
 100-110 mmHg  -4.7  
 110.1-118 mmHg  -5.7  
 >118 mmHg  -6.4  
ACE-inhibitors/ARB   0.25 
 No use -4.9  
 Regular use  -5.5  
Albuminuria   <0.01 
 <500 mg/24 h -4.4  
 500-<1000 mg/24 h -3.2  
 1000 - <2000 mg/24 h -4.4  
 ≥2000 mg/24 h -6.4  
Plasma albumin  <0.01 
 ≤31 gram/L -6.8  
 32-36 gram/L -6.7  
 37-39 gram/L -4.9  
 ≥40 gram/L -4.3  
Blood hemoglobin   0.66 
 ≤102 gram/L -5.7  
 103-113 gram/L -5.1  
 114-125 gram/L -5.3  
 ≥126 gram/L -4.7  
 
* ml/min/1.73 m2, CCI (Charlson co-morbidity index score) 
# P-value for comparisons of patients belonging to different categories was 
estimated from quintile regression 
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We also estimated the progression rate using a mixed effects model with random 
intercept and slope. In this model we were able to include all 920 patients since 
the estimate for those with only a first eGFR value is based upon the slopes of 
patients with similar characteristics in the cohort. The mixed effects model also 
takes account of the different length of follow-up time between subjects and thus 
makes the estimate more stable.  
 
The unadjusted progression rate using the mixed effects model (n=920) was -
4.2ml/min/1.73 m2 per year (SD 2.5). The same covariates (age, sex, primary 
renal disease, albuminuria, plasma albumin, blood pressure) were significantly 
associated with differences between categories as in the linear regression 
analysis. However in multiple regression analysis, only age, blood pressure and 
albuminuria remained significantly associated with the progression rate. All of 
these variables also showed a significant trend associated with progression rate; 
higher age was associated with a slower progression rate whereas higher blood 
pressure and albuminuria was associated with a more rapid progression rate.  
 
5.2.1.2 Risk of Renal Replacement therapy 
 
Patients with low eGFR at the beginning of the follow-up had, as expected, 
higher risk of receiving RRT than patients with high eGFR. Age was inversely 
related to risk of RRT (adjusted hazard ratio (HR) for patients ≥65 years relative 
to patients <45 years 0.7; 95% CI 0.6-0.9). Men had a higher risk of RRT than 
women (HR 1.6; 95% CI 1.4-1.9), and patients with diabetic nephropathy higher 
risk of RRT compared to subjects with glomerulonephritis (HR 1.24; 95% CI 
1.02-1.51) and other primary renal diseases. 
 




Of the 920 patients eligible for the follow-up we excluded 62 with follow-up 
shorter than 14 days and 57 for whom we were unable to find the medical records 
or a second S-Cr measurement, leaving 801 (68%) patients for inclusion in our 
analysis. The excluded patients (n=119) did not differ significantly with respect 
to age, sex, primary renal disease, or acetaminophen and aspirin use compared 
with the patients included in the analyses. The unadjusted progression rate based 
on simple linear regression among regular users of acetaminophen at the time of 
inclusion in the cohort was -5.2 ml/min/1.73m2 per year. Non-regular users of 
acetaminophen at inclusion progressed at -5.1 ml/min/1.73m2 per year. The 
results from the multivariate mixed effects model is shown in Table 7. 
 
72 patients were regular users of acetaminophen at inclusion and continued to use 
the drug during follow-up. The mean adjusted progression rate of these patients 
was -2.9 ml/min/1.73 m2 per year, which was significantly lower compared to 
patients with no regular use at inclusion or during follow-up. Exclusion of 50 
patients who were users both of acetaminophen and aspirin and thus restricting 
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the analysis to solely acetaminophen users, did not make the estimates change 
substantially; the adjusted progression rate among regular users was -4.0 
ml/min/1.73 m2 per year (95% CI -5.1, 2.9) 
 
Table 7.  Progression rate for CKD patients with different levels of lifetime 
cumulative acetaminophen use 
 
Acetaminophen   Progression rate§ 
(95% CI) 
P-value 
 Never used -4.5 (-5.0, -4.0) Ref. 
 1-99 g -4.7 (-5.2, -4.1) 0.7 
 100-499 g -3.9 (-4.7, -3.1) 0.2 
 500-2999g -3.9 (-5.1 -2.6) 0.3 
 ≥3000g -4.3 (-5.6, -2.9) 0.7 
   P-value trend 0.24 
    
 No regular use -4.5 (-4.9, -4.2) Ref. 
 Regular use -3.6 (-4.4, -2.8) 0.04 
 
§ ml/min/1.73 m2 per year; mixed effects model, adjusted for age, sex, ACE/ARB 
use, and blood pressure at inclusion. 
 
Regular acetaminophen use was associated to a slower progression rate regardless 
of whether we stratified on eGFR at inclusion, primary renal disease, sex or age. 
For patients who were older and had nephrosclerosis, the difference in retardation 
in progression rate was statistically significant. The stratified analysis on 
acetaminophen regular use is shown in Table 8. 
 
 
Table 8. Difference in progression rate compared to non-regular users of 
acetaminophen among patients with different baseline characteristics 
 
Acetaminophen Regular use  Coefficient§ 
(95% CI) 
P-value 
<45 years 0.32 (-2.1, 2.7) 0.79 
45-64 years 0.25 (-1.3, 1.8) 0.75 
≥65 years 1.6 (0.4, 2.7) 0.006 
Men 1.2 (-0.2, 2.5) 0.10 
Women 0.34 (-0.8, 1-5) 0.55 
Single substance acetaminophen use 0.53 (-0.6, 1.7) 0.37 
Diabetic nephropathy 0.45 (-1.1, 2.0) 0.6 
Nephrosclerosis 3.2 (1.3, 5.3) 0.002 
Glomerulonephritis 0.93 (-1.7, 3.5) 0.48 
 
§ Difference in progression rate (ml/min/1.73 m2) per year compared to the 
reference group (non-regular users). Negative values mean faster progression, 
and positive values mean slower progression compared to the reference. 
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Lifetime cumulative dose of acetaminophen overall did not show any effect on 
the progression rate. For patients who had used >3000 gram acetaminophen and 
were non-regular users of aspirin the fully adjusted progression rate was 
0.43ml/min/1.73 m2 per year faster (-2.2, 1.3) compared to non-users. For 
patients with diabetes who had used >3000 gram acetaminophen the difference in 
progression rate compared to non-users with diabetes was -1.2 ml/min/1.73 m2 
per year (-4.3, 1.9) whereas it was associated with slower progression rates both 
among patients with glomerulonephritis and nephrosclerosis. Stratification on sex 
or age did not change the pattern of a slight, non-significant effect of 




Based upon the linear regression, the unadjusted progression rate for patients who 
used aspirin regularly was -4.4ml/min/1.73 m2 per year compared to -5.3 
ml/min/1.73 m2 per year among non-regular users.  In Table 9 the adjusted 
progression rates (mixed effects model) associated with different lifetime 
cumulative doses of aspirin is presented. There was no difference in progression 
rate among subjects with different lifetime cumulative aspirin use, but patients 
who used aspirin regularly at inclusion had a significantly slower decline in 
eGFR compared to non-regular users. When we stratified these results on whether 
the patients were low dose aspirin users or regular aspirin users, we found that it 
was low dose aspirin use that was associated with slower progression. Restricting 
the analysis to regular users of only aspirin and not acetaminophen made the 
coefficient no longer significant, but still positive (0.61, 95% CI -0.1, 1.4).  
 
 
Table 9. Progression rate for CKD patients with different levels of lifetime 
cumulative aspirin use and aspirin regular use 
 
Aspirin  Progression rate§ 
(95% CI) 
P-value 
Never used -4.8 (-5.4, -4.3) Ref. 
1-99 g -4.3 (-4.9, -3.7) 0.2 
100-499 g -4.1 (-4.8, -3.5) 0.1 
500-2999g -4.1 (-5.2 -3.0) 0.3 
≥3000g -4.1 (-5.6, -2.7) 0.4 
  P-value trend 0.12 
Aspirin regular use   
No regular use -4.6 (-5.0, -4.3) Ref. 
Regular use -3.8 (-4.4, -3.3) 0.02 
Only low-dose -3.7 (-4.3, -3.1) 0.01 
Also during follow-up -3.5 (-4.2, -2.9) 0.004 
 
§ ml/min/1.73 m2 per year; mixed effects model, adjusted for age, sex, ACE/ARB 
use, and blood pressure at inclusion. 
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For patients without cardiovascular disease who used aspirin regularly, the 
progression rate was 0.74 ml/min/1.73 m2 per year (-0.3, 1.9) slower compared to 
non-regular users while the progression rate among regular aspirin users with 
cardiovascular disease only differed by 0.24ml/min/1.73 m2 per year (-0.8, 1.2) 
compared to non-regular users. Analyses stratified by gender demonstrated that 
women that used aspirin regularly had a 0.41 ml/min/1.73 m2 per year (-0.6, 1.4) 
slower progression rate compared to non-regular users; men who used aspirin 
regularly slowed their progression rate by 1.08 ml/min/1.73 m2 per year (0.2, 2.0) 
compared to non-regular users. Comparing the effect of regular aspirin use in 
patients with different primary renal disease we saw a slight positive effect in all 
the investigated groups, but among patients with glomerulonephritis the effect on 
progression rate was even more pronounced (difference compared to non-regular 
users 1.95 ml/min/1.73 m2 per year, 95% CI 0.5, 3.4, p=0.007).  
 
For aspirin users who continued to use aspirin during follow-up, the protective 
effect was most evident among patients with the highest lifetime cumulative 
dose. Patients who had used >3000 g aspirin and continued to use aspirin had a 
1.95 ml/min/1.73 m2 per year (95% CI -0.3, 4.2) slower progression rate 
compared to never users. Restricting the analysis to users of only aspirin and not 
acetaminophen did not change the estimates substantially. Also here, patients 
with glomerulonephritis benefited the most of continued aspirin treatment; all 
coefficients were 1.0 - 4.3 ml/min/1.73 m2 per year slower for aspirin users of 
different cumulative dose.  
 
5.2.3 Occupational lead exposure (III) 
 
5.2.3.1 Risk for CKD development 
 
The unadjusted Odds ratio (OR) for CKD was 0.94 for lead exposed compared to 
never-exposed. In the final multivariate analysis adjustments for age, sex, alcohol 
consumption, diabetes, level of education and BMI did not change the OR 
substantially (OR 0.97, 95% CI 0.7-1.4). The OR for subjects exposed to lead at 
the highest average level (7.5-75% of OEL) did not reach significance level (OR 
1.09, 95% CI 0.6-1.9). For subjects who were exposed at the highest lifetime 
cumulative exposure level (>0.15mg/m3*year) the odds for CKD was below unity 
(OR 0.69, 95% CI 0.4, 1.3). Restricting the analysis to subjects exposed at the 
highest level we found that there were 9 CKD patients and 14 controls that had 
been exposed at an average level >50% of OEL. The OR associated with CKD in 
this high average exposure group was 0.73 (0.3-1.8). Among subjects with a 
lifetime cumulative dose at the OEL for at least 5 years the OR for CKD was 0.54 
(95% CI 0.2, 1.6). The OR associated with different subgroups are presented in 
Table 10. 
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Table 10.  Odds Ratios for different diagnosis of CKD associated with 
occupational lead exposure 
 
Subgroup1 Odds Ratio (95% CI
 ) §
Lead exposure 
Odds Ratio (95% CI ) § 
Highest average lead exposure 
Diabetes 
nephropathy 0.85 (0.5-1.4) 1.1 (0.5-2.2) 
Glomerulonephritis 0.93 (0.6-1.5) 0.99 (0.5-2.1) 
Nephrosclerosis 1.17 (0.6-2.1) 1.36 (0.6-3.2) 
>60 years at 
inclusion 1.03 (0.7-1.7) 1.05 (0.5-2.1) 
1 Restricted analysis 
§ Adjusted for age, sex, alcohol use, smoking and BMI 
 
 
5.2.3.2 Risk for progressive disease and RRT 
 
The progression rate did not differ significantly for any of the lead exposure 
groups we studied compared with non-exposed (Figure 5).  In stratified analyses 
by primary renal disease the decline in eGFR among patients with diabetic 
nephropathy was 0.39ml/min/1.73m2 per year (95% CI -2.7, 1.9) faster among 
lead exposed compared to non- exposed. The difference in progression rate was 
0.17 ml/min/1.73m2 per year faster among lead exposed patients with 
nephrosclerosis while the coefficient was positive in lead exposed patients with 
glomerulonephritis. Among younger patients (<45 years) the lead exposed 
patients progressed 1.79 ml/min/1.73m2 per year faster (95% CI -7.3, 3.7) but due 
to the very limited number of exposed patients in that group the confidence 
intervals were very wide. There was no difference in progression rate among lead 
exposed with different smoking habits, or eGFR at inclusion.  
 
In a Cox proportional hazards regression model we estimated the adjusted hazard 
rate (HR) for RRT start associated with occupational lead exposure and the 
different groups of lead exposure levels. In an analysis adjusting for age, sex, 
smoking and ACE/ARB use the HR was 0.92 (95% CI 0.7, 1.2) for lead exposed, 
HR 0.83 (95% CI 0.5, 1.3) for patients with the highest cumulative lead exposure, 
and HR 0.89 (95% CI 0.6, 1.3) for patients with the highest average lead 
exposure compared to non-exposed patients.  
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Figure 5. Decline in eGFR (ml/min/1.73 m2 per year) and 95% confidence 
interval for patients never exposed to occupational lead, compared to groups of 



















Adjusted for age, sex, ACE/ARB use and smoking. NOTE! The confidence 
intervals in the published Ms IV are wrong for the mean exposure group, these 
are the correct values.  
 
 
5.3 MORTALITY (I, IV) 
 
The all-cause mortality was high in the cohort. One-year survival was 97% and 
five-year survival 61%. By the end of 2005, only 45.6% of the patients were still 
alive (Figure 6). We were able to find the registered primary cause of death in the 
National Registry for causes of death for 456 (91%) of the 500 deaths by 31 Dec 
2005. The most common cause of death was from cardiovascular disease 
(45.8%), followed by diabetes (22.5%), kidney diseases (10.3%) and 
malignancies (9%). The proportion of patients with an infection as the primary 
cause of death was very low, only 3.1% of the patients in the cohort.  
 
In the first descriptive paper (I) we analyzed risk of death until 31 December 
2002 associated with a small number of patient characteristics at inclusion. We 
found a significantly higher mortality with older age (HR for age 65 or older 
versus age <45 years =5.2; 95% CI =3.1-9.0), BMI ≤ 20 kg/m2 versus 20.1-25 
kg/m2 (HR=1.96; 95% CI =1.4-2.8), and underlying diagnosis of diabetes relative 
to glomerulonephritis (HR=3.1; 95% CI =2.3-4.3) when adjusting for all other 
variables and transplantation during follow-up. Obesity (BMI > 30 kg/m2) at 
inclusion was borderline significantly protective (HR=0.7; 95% CI =0.5-1.0). 
GFR at entry was unrelated to mortality. In further analyses we extended the 
analysis time to 31 December 2005 and included all other baseline variables 
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albumin and blood hemoglobin, use of ACE/ARB and other antihypertensive 




Figure 6. Survival in a cohort of CKD patients, who were included when the 




















In univariate analysis, patients with diabetic nephropathy, lower levels of plasma 
albumin and blood hemoglobin, lower level of education, alcohol intake and 
BMI, and patients with higher CCI, blood pressure, cumulative smoking and 
albuminuria had a significantly elevated HR of death. The results from the 
multivariate analysis are presented in Table 11.  
 
Compared with the general Swedish population, the members of this cohort had a 
substantially higher risk of dying as the (Standardized Mortality Ratio [SMR] = 
8.3; 95% CI=7.5-9.2). This excess risk was even more pronounced in the younger 
age categories (SMR=20.6 in age < 45 [95% CI 11.0-35.3]) and among women 












































Table 11. Adjusted Mortality for 920 CKD patients included when their serum 
creatinine first passed 300µmol/l for men and 250µmol/l for women, followed 
through Dec 31 2005 and censored at date of kidney transplantation. 
 







< 45 years 1 Ref.  
45-64 3.0 1.6-5.7  Age 
≥65 4.2 2.2-8.3 <0.0001 
Sex Men 1.1 0.8-1.5  
<20 1 Ref  
20-24.9 0.4 0.3-0.7  
25-29.9 0.3 0.2-0.5  
Body mass 
index (kg/m2) 
≥30 0.2 0.1-0.4 <0.0001 
No use 1 Ref  
Low 0.7 0.5-1.0  Alcohol use 
High 0.9 0.6-1.3 0.72 
Never smoked 1 Ref  
Low 0.8 0.6-1.1  Smoking 
High 1.0 0.7-1.4 0.89 
≤9 years 1 Ref  
9-12 0.7 0.4-1.0  Education 
≥ 13 0.9 0.5-1.4 0.18 
<100 1 Ref  
100-109.9 0.9 0.6-1.3  




≥118 0.7 0.5.1.1 0.26 
ACE/ARB use Yes 1.3 1.0-1.8  
2 (no other) 1 Ref.  
3-4 2.2 1.4-3.6  Co-morbidity score 
>4 4.4 2.5-7.2 <0.0001 
≤102 gram/L 1 Ref  
103-113 gram/L 0.7 0.5-1.0  




≥126 gram/L 1.0 0.6-1.5 0.78 
≤31  1 Ref  
32-36  0.8 0.5-1.1  
37-39  0.7 0.5-1.1  
Plasma 
albumin (g/L) 
≥40  1.0 0.7-1.5 0.91 
Albuminuria High level 1.7 1.2-2.4  
Glomerulonephritis 0.3 0.2-0.5  
Diabetes 1 Ref  
Hypertension 0.8 0.6-1.2  
Primary renal 
disease 
Other/Unknown 0.8 0.6-1.2  
*Adjusted for all other variables and eGFR at inclusion  
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5.3.1 Mortality before Renal Replacement Therapy was 
initiated 
 
By December 31 2005, 100 patients (9.2%) died before RRT was initiated. We 
found the cause of death for 94 of these patients. The most common cause of 
death among patients who died before initiation of RRT was cardiovascular 
diseases (51%), followed by malignancy (20%) and diabetes (12%). Renal failure 
or uremia was considered the primary cause of death in 8.5% of the patients who 
died before RRT.  
 
Not surprisingly, patients who died before RRT was initiated were older, had 
lower levels of education and more often diabetes, cardiovascular disease, and 
hypertension and thus a higher CCI score. Plasma albumin, blood hemoglobin 
was not different at inclusion compared to patients who survived without RRT 
and higher than patients who started RRT. Albuminuria was significantly higher 
among patients who died before RRT was initiated compared to those who 
survived without RRT, but lower than among those who initiated RRT. During 
follow-up, the patients who died before RRT lost significantly more weight 
(mean weight loss 2.4 kg (SD 7.7)) compared to patients who started RRT (mean 
weight loss 0.8 kg (SD 5.3)) and patients who survived without RRT (mean 
weight gain 2.1 kg (SD 6.4)). 
 
In a multivariate analysis, the covariates significantly associated with an 
increased risk of death before RRT was initiated was higher age, low BMI (BMI 
<20 kg/m2 HR 5.9 [95% CI 1.6-21.6] compared to BMI>30 kg/m2) and high CCI 
(CCI score >4 HR 3.2 [95% CI 1.1-9.3] compared to CCI score 2). Patients with 
glomerulonephritis had a significantly lower risk of death before RRT was 
initiated compared to patients with diabetes nephropathy.  
 
Estimated GFR was also significantly associated to mortality before RRT was 
initiated (Figure 7). In a Cox proportional Hazards regression model where eGFR 
was treated as a time-dependent covariate (each time a patient was moved from 
one eGFR strata to another we censored and restarted the patient’s survival time 
in the new strata) the HR for eGFR <7.5 ml/min/1.73 m2 was 9.0 (95% CI 4.4-
18.1) compared to eGFR ≥15 ml/min/1.73 m2. The HR for eGFR 7.5-9.9 
ml/min/1.73 m2 was 1.21 (95% CI 0.5-3.0) and for eGFR 10-14.9 ml/min/1.73 m2 
1.1 (95% CI 0.6-1.9) relative to eGFR ≥15 ml/min/1.73 m2 adjusting for age, sex, 
CCI, BMI, diabetes, smoking, alcohol use, blood hemoglobin, plasma albumin 
level, and level of education. In a time-dependent model where only patient 
survival time was counted when eGFR had fallen to eGFR 10 ml/min/1.73 m2, 
the HR for eGFR <7.5 ml/min/1.73 m2 was 4.65 (95% CI 1.28, 9.49) compared 


























Figure 7. Kaplan-Meier patient-survival curves by level of estimated glomerular 
filtration rate (eGFR, ml/min/1.73 m2) for 901 stage 4-5 CKD patients not yet 
subjected to renal replacement therapy (RRT). Patients who moved from one 
eGFR stratum to another were censored in the old stratum and re-started from 

























5.3.2 Mortality in relation to dialysis initiation  
 
5.3.2.1 Initiation of dialysis 
 
In a first analysis we investigated mortality for patients who started versus not 
started RRT. Dialysis start was treated as a time-dependent covariate, and 
survival time was censored at the date when a patient was either transplanted or 
ended follow-up (June 1, 2003) without having started RRT. The Kaplan-Meier 
curve comparing the mortality rates for patients without and with dialysis is 
presented below (Figure 8). In the Cox proportional hazards regression model, 
the HR for starting dialysis was 2.64 (95% CI 1.80, 3.89) relative to patients who 
had not started dialysis after adjustments were made for the differences in 
baseline characteristics.  
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Figure 8. Kaplan-Meier survival curves for 901 stage 4-5 CKD patients without 
renal replacement therapy (RRT) and after initiation of such therapy. In the “No 
RRT” category, censoring occurred at initiation of RRT. If the RRT was dialysis, 
the patients started at time 0 in the “Dialysis” category, in which censoring 
























5.3.2.2 Timing of initiation of dialysis 
 
In further analyses we treated both eGFR and dialysis initiation as time-
dependent variables. The analysis compared patients who had eGFR ≤20 
ml/min/1.73m2, and started dialysis at different eGFR levels along the disease 
trajectory. Since late start was defined as dialysis initiation at eGFR <7.5 
ml/min/1.73 m2 we regarded any patient time within eGFR 20-7.5 as “candidate 
for early dialysis” and any time after 7.5 as “candidate for late start dialysis”. The 
moment the patient started dialysis the patient’s survival time was restarted in the 
“early dialysis start” or “late dialysis start” group. To be able to properly adjust 
for the differences in progression rates, which in turn affected the probability of 
reaching the late start dialysis stage, we included in our models both progression 
rate and eGFR at start of follow-up.  
 
The results of the multivariate analysis are presented in Table 12. Relative to 
patients who started early, late starters had a non-significantly lower risk of death 

























Table 12.  Time-dependent analysis of timing of dialysis initiation in a cohort of 
901 unselected patients with CKD 
 
 









0.35 0.23-0.51  
Subject to early 
start dialysis‡ 
1 Ref.  
Candidate for 
late dialysis§ 
0.95 0.53-1.67  
Clinical status 
Subject to late 
start dialysisª 






0.97# 0.94-1.00 0.12 
<2.77 1 Ref.  
2.77 - 4.60 1.81 1.19-2.73  




per year) ≥6.02 1.54 1.06-2.21  
 
*ml/min/1.73m2 estimated by the 4 variable MDRD [28]  
† 20≥eGFR≥7.5 ml/min/1.73 m2 and not subjected to renal replacement therapy 
(RRT) 
‡ 20≥eGFR≥7.5 ml/min/1.73 m2 at initiation of dialysis 
§ eGFR <7.5 ml/min/1.73 m2 and not subjected to RRT 
ª eGFR <7.5 ml/min/1.73 m2 at initiation of dialysis 
# HR per ml/min/1.73 m2 change of eGFR, adjustments are made for age, sex, 
BMI, alcohol use, cumulative smoking, primary renal disease, level of education, 
eGFR first inclusion, progression rate, and CCI. 
 
 
We also did a sensitivity analysis where we included only patients who had 
passed ≤15ml/min/1.73m and ≤10ml/min/1.73m2 to see if the risk associated with 
late start dialysis changed. The risk estimate did not change substantially; HR 
(late start) 0.86; (95% CI 0.66, 1.12), and HR (late start) 0.88; (95% CI 0.65, 
1.18) respectively compared to early dialysis start. The same pattern of a slight 
non-significant protective effect of late dialysis start was observed in both sexes, 
in patients with or without diabetes nephropathy, and for different age categories. 
We also excluded all patients with imputed eGFR values without any substantial 
change in the results.  




6.1 METHODOLOGICAL CONSIDERATIONS 
 
When testing a hypothesis the best method to investigate whether an exposure 
causes an outcome is to conduct an experiment. In medical research however, 
there are ethical considerations; sometimes an experiment is not possible to 
perform without putting one of the exposure-groups at risk. There are also 
economical considerations as randomized controlled trials sometimes are costly. 
[242]Observational studies investigate exposures that occur within a population 
without an experimental design. This means that exposed and non-exposed 
individuals are most likely different. In a perfectly conducted randomized 
controlled trial, the experimental design results in two equal groups in every 
aspect be the exposure. In observational studies one has to consider the 
differences between the two groups and adjust for them in the analyses. Another 
aspect of the observational study is the study setting and selection of study 
participants. If the study subjects are selected more frequently because they are 
exposed, or if they belong to certain risk populations the results will be invalid.  
 
6.1.1 Study design 
 
Most of the studies we performed were cohort studies (I, II, III, IV), but we also 
included a case-control study in one of the papers (III). Case-control studies are 
usually performed in medical research when the studied disease is rare but the 
exposure quite common. The principle is to select cases that have developed the 
disease and compare with control subjects without the disease that derive from 
the same study base. Differences between cases and controls have to be adjusted 
for by statistical methods, usually in logistic regression analysis. Unmeasured 
differences between cases and controls cannot be adjusted for, and thus may 
result in so-called “residual confounding”. A common pitfall with case-control 
studies is in the flawed selection of study subjects; both for cases and 
controls.[243]  
 
6.1.1.1 Selection of cases and controls 
 
The cases in our study (patients with CKD) have to be as close to “incident” as 
possible. By “incident” we mean, “newly diagnosed”. It may be easy to find 
incident cases with appendicitis or fractures, but it is problematic to find a 
subject with incident CKD; there are so few early symptoms. We decided to 
define incident as the first time a patient passed a predefined S-Cr value. 
Although S-Cr is not the perfect measure of renal function it is a common test 
performed at a wide range of suspected clinical conditions as well as screening in 
certain risk groups such as hypertensives and diabetics. Since the S-Cr varies 
with muscle mass, we had different cut-offs for men and women.  The serum 
creatinine limit was set high enough to ensure inclusion of as many true positive 
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individuals as possible (high sensitivity), but low enough to find the patients 
before they had reached ESRD with need for dialysis. The reason one wants to 
find incident patients in case-control studies instead of prevalent (all living 
patients with CKD) is that prevalent CKD patients are different. Among prevalent 
cases, there is an over-representation of those with milder and slowly progressive 
disease. In Sweden the prevalence of diabetes nephropathy and 
glomerulonephritis among all patients in RRT is 19% and 26% respectively, 
while the yearly incidence of patients with diabetic nephropathy is 24-27% and 
glomerulonephritis 11%.[6] We aimed at finding all incident patients in Sweden. 
While the true incidence of CKD in Sweden is not known, our study results 
suggest 102-115 per million population year (pmp). This is lower than the 
incidence of ESRD based upon the Swedish Renal Registry, where the incidence 
rate was 118 pmp in 1997, and 124 in 1998. Considering that 13% of the 
prevalent dialysis population was more than 74 years old in 1997 and that the 
yearly incidence of patients >65 years old was 367 pmp in 1997,[6] we believe 
we found most patients with incident CKD.  
 
The controls in a case-control study also have to be carefully selected. In a 
population-based study such as ours it is essential that they derive from the same 
study base of native Swedes, 18-74 years, living in Sweden May 1996-1998. To 
obtain this was rather easy giving the structure and accuracy of the up-dated 
Swedish population register. We calculated the study base to 5.3 million people, 
and controls were randomly selected from the study-base on three occasions 
during the study period (1996-1998). Because we wanted to obtain the same age 
and sex distribution, the controls were frequency matched on these variables. The 
definition of a control is that he or she does not have the studied disease. We did 
not measure S-Cr on the controls. The prevalence of existing CKD stage 4-5 (as 
the cases selected for the study) in a population has been shown to be 0.16%[12] 
and none of the controls had known CKD based on the interview data. Even 
supposing some of the controls in fact had CKD it would at most be 1 or 2 
subjects and that would not have affected the results to any great extent. 
 
6.1.1.2 Cohort studies 
 
In a prospective cohort study a group of individuals are followed forward in time 
and events that occur along the path are registered. In medical research, cohort 
studies may be used when studying unusual exposures and relatively common 
diseases. The problem with cohort studies is that they usually require a large 
number of participants for enough events to happen, and that they are expensive 
and time-consuming to conduct. One can make internal comparisons; 
comparisons of individuals within the cohort – those who developed the event 
and those who did not. Another way is to make external comparisons, for 
example with another cohort or the general population. Our cohort consisted of 
patients with incident CKD and we made internal comparisons. The advantage 
with analyses in our cohort was that although we studied relatively few patients, 
virtually all had a disease progression, and mortality and RRT incidence was 
high. 
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 It is important that the registration of events is complete and not depend on 
exposure or disease status. In our survival analyses we used the continuously up-
dated population register, and the Swedish Renal Register, which resulted in no 
follow-up losses. The eGFR was estimated repeatedly during follow-up so we 
could compute an individual progression rate. We used S-Cr values taken in 
regular clinical follow-up abstracted from the medical records during 2003-2005. 
The number of measurements varied between individuals in the medical records, 
but we wanted to register the same number of measurements for all participants 
regardless of disease or exposure status; we hypothesized that “sicker” patients 
would have more values than “healthier” patients giving rise to different accuracy 
of the progression rates and differential misclassification (see section 6.1.2.3). 
The resulting dataset was unbalanced since all individuals had unequal inter-
measurement intervals. The repeated, correlated and unbalanced data could be 
managed using advanced statistical models, now available in most statistical 
software packages. We tried to find all medical records but were unable to find 
some (n=57). If the medical records were missing completely at random (not 
because of any relation to disease or exposure status) they should not affect the 
result of the estimate. We studied the missing records and found that there was no 
significant difference in age, sex, analgesic use, and time to RRT or death among 
patients with a missing record compared to those with a record. Patients with 
missing records though, had slightly lower eGFR and BMI at inclusion. However, 
none of the variables were independently associated with missingness. Thus, we 




By validity one means that the results adhere as close to the true results as 
possible; inferences are said to possess internal validity if a causal relation 
between two variables is properly demonstrated.[243] External validity is how 
the results apply to settings other than those studied, generality. Internal validity 
may be low due to systematic errors, bias, and these one must consider when 
designing and analyzing the study. There are several types of bias that may apply 
to both case-control and cohort studies. 
 
6.1.2.1 Selection bias 
 
Selection bias refers to the problem that differences between groups may exist 
already before the study takes place, and that preferential recruitment of patients 
belonging to these groups may be responsible for the observed effect. In case-
control studies, one example could be the choice to use hospital controls. 
Subjects belonging to certain socio-economic groups or exposures may be over- 
or under represented in some hospitals and clinics resulting in selection-bias. In 
our study we would have had problems with selection bias in the case-control 
study (IV) if patients or controls that declined to participate or suffered from 
early death were different in for example lead exposure compared to those 
included in the cohort. The non-participation rate was however low, and 
comparable between cases and controls. Selection bias relating to differential 
recruitment of subjects with low socio-economic status is unlikely because the 
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health system in Sweden gives essentially equal access to health care regardless 
of residence or income, [233]and virtually no private actors were involved here.  
 
Another selection problem that mainly pertains to the cohort studies (I-IV) would 
be if there was a preferential inclusion of patients who had either severe or mild 
disease; selection on the outcome. However, even though the range of the eGFR 
was wide at inclusion, most of the patients were included close to the eGFR 
corresponding to the S-Cr limit. With a pre-defined cut-off at S-Cr 250-300 
µmol/l we aimed at an eGFR level of approximately 20 ml/min. We assumed that 
with such levels of S-Cr, the cause of the elevation was most likely to be kidney 
disease. Also, patients with such values were more likely to have been referred to 
a Renal Unit or Department. The timing when patients were included depended 
both on their progression rate, and the interval between their S-Cr measurements. 
Patients who were unaware of their renal disease and had high progression rates 
were sometimes included at a very late stage while patients with a more severe 
disease would probably have their serum creatinine checked more often, and thus 
were more likely to be included close to the pre-defined limit. Looking at our 
inclusion data, we find that patients with high eGFR at inclusion more often had 
a faster progression rate, except for the group with the lowest eGFR values, in 
which the mean progression rate also was almost as high. In the studies of 
analgesics (II) and lead exposure (III), there were however no difference in eGFR 
at inclusion for the different analgesic or lead exposure groups and the CCI score 
was not associated to eGFR at inclusion.  We excluded those with a follow-up 
less than 14 days because we thought that it was not meaningful to calculate a 
progression rate with lesser time (II, III). This could have introduced bias if the 
“sickest” (and with highest exposure levels) were excluded. To analyze the effect 
of possible “selection of the fittest” we performed sensitivity analyses where we 
excluded individuals with <3 months of follow-up or eGFR <7ml/min/1.73 m2 at 
inclusion. The results of these additional analyses were virtually the same. Since 
we obtained the other outcome data (mortality and start of RRT and 
transplantation) from linkages to registries, there was no difference in this 
information between the different exposure groups.  
 
 
To avoid selection on the exposure we chose to use self-reported information at 
inclusion. Since 42% of the patients in the cohort were dead by the time we did 
the first linkage in 2002, introducing a second exposure assessment during 
follow-up would have resulted in selective information on follow-up data for the 
surviving proportion. To have equal information from the patients on drugs used 
during follow-up we used information from the medical records. 
 
In survival analyses there are other selection problems to keep in mind. One is 
called “survivor treatment selection bias”, and refers to the common problem that 
the longer a patient survives the greater is the probability to receive a 
treatment.[244] If you want to study treatment effects, this bias will most likely 
favor the treatment group if you not adjust for it by study design. One way to 
adjust is the use of time-dependent models where the survival probability among 
treated is compared to the survival probability of non-treated who have survived 
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thus far. Another problem linked to survival studies is “lead-time bias”.  To 
illustrate lead-time bias, one can think of cancer screening. A woman (A) who is 
screened for breast cancer is diagnosed with a small sub-clinical tumor. Another 
woman (B) discovers a palpable tumor in her breast and is later diagnosed with 
breast cancer. If these two women are included in a study at the “date of 
diagnosis”, woman A will have longer survival because she was detected “earlier 
in the course of disease”. The studies of early and late dialysis start faced the 
same problem as they included incident dialysis patients. The patients included 
early were “detected” earlier and were favored in the survival analyses.  
 
In our study of early and late dialysis start (IV) we believe that lead-time bias 
was unlikely to affect the estimates because we included the patients when they 
passed a predetermined S-Cr level before dialysis start. Although estimated GFR 
differed significantly between the two groups at first inclusion, late starters had 
lower eGFR than early starters and lead-time bias, if any, would in that case 





If exposed and non-exposed differ in some other respect related to the studied 
disease there is a possibility of confounding. For a variable to be a true 
confounder is has to be associated to both the exposure and the disease, and not a 
consequence of the exposure. In our studies we have several potential 
confounders. Lead exposed patients are for example more often smokers, and 
smoking is also independently associated to progression rate. The ways to deal 
with confounding in analyses are regression or stratification. If we had not 
adjusted (by regression analysis) for smoking in our model we may have 
observed a faster progression rate for lead exposed that was really caused by 
smoking. It is only possible to adjust for measured confounders, and unmeasured 
factors may still be present and obscure a true relationship. In our models we 
tried to adjust for as many covariates as possible known to us to be associated to 
our examined exposures and our outcomes.  
 
Confounding by indication is common in observational studies.[245] Patients 
who start dialysis early don’t do that solely by chance, but because they possess 
some characteristics that may have made their nephrologists chose an early start. 
These characteristics are often related to severity of disease. Sicker patients are 
often treated differently to healthier patients. If we do not adjust (by regression or 
stratification) for the factors relating to severity of disease the results will be 
confounded. Sometimes it is not possible to adjust for everything that the 
nephrologists may have in mind when assigning early or late dialysis start. There 
may not be enough resolution in the data to measure small clinical differences, 
and these small differences will cause “residual confounding”. In our analysis of 
early versus late start of dialysis (II) there may be residual confounding due to 
insufficient clinical information on co-morbid conditions and other laboratory 
parameters. Since late starters more often are healthier compared to early starters, 
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correction for residual confounding will most likely dilute the differences 
between early and late start even more.  
 
Another type of confounding is protopathic bias - factors or symptoms linked to 
precursor stages of the disease cause patients to have a greater chance to be 
exposed. In the case-control study by Fored et al [185]investigating analgesic 
exposure and risk for CKD it was found that the odds for regular users of 
acetaminophen of developing CKD was 2.5 compared to non users. If early 
symptoms of CKD (or the disease that gave rise to CKD e.g. diabetes or 
vasculitis) caused the subject to use more analgesic drugs it would cause 
protopathic bias. Indeed, the greatest risk for CKD in Fored's study was found 
among diabetics and patients with systemic diseases - diseases that may cause 
painful symptoms. However the OR exceeded one in all subgroups studied, and 
remained significant overall in analyses excluding any exposure within the 
closest ten years before study inclusion.  
 
In our follow-up of the same patients (II), neither regular nor a high cumulative 
analgesic use was associated with a faster progression rate. One of the 
explanations of the differences in results may be that protopathic bias was 
responsible for the results in the first case-control analysis. Another explanation 
is that the mechanisms that initiate the early renal damage, and that make the 
renal disease progress in the advanced stages are different. Protopathic bias is not 
likely to obscure a true relationship in our follow-up study of analgesic exposure. 
In order to do that, patients with slowly progressing disease had to consume more 
analgesic drugs.  
 
Protopathic bias in the occupational lead investigation (III) would mean that 
patients with early symptoms of CKD became less likely to become lead workers 
or to continue the exposure. It is possible that a patient with diabetes or vasculitis 
would have a lesser chance of getting a job and that would indeed cause under-
representation of lead exposed among the cases. Lead workers have their blood 
checked regularly and there is a chance of discovering CKD, which could cause a 
recommendation to change job. However, this would reduce the OR in the 
analysis of cumulative exposure, but it does not explain our lack of association of 
ever versus never exposure and average lead exposure since we recorded a 
lifetime work history. Protopathic bias cannot explain that we found no 
difference in progression rate when we performed internal comparisons of 
exposed and non-exposed CKD patients. 
 
In case-control studies collection of information regarding the exposure is often done 
retrospectively. A subject who has recently been diagnosed with a disease may then 
be more likely to remember and give weight to earlier exposures. When cases and 
controls are compared this “recall bias” may result in spurious associations. In our 
lead exposure study (III) we do not feel that recall bias explained our results because 
then the CKD patients would have been less likely to remember earlier work-place 
exposures. In the follow-up studies the information on analgesic drugs, lead exposure 
and other covariates was collected before we started follow-up, prospectively, and the 
outcome could not have influenced the information given. Exposed and non-exposed 
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were interviewed in a standardized manner, and the patients were not aware of the 




There are two types of misclassification, differential and non-differential. By 
differential misclassification we mean that information on exposure or outcomes 
was collected or classified differently for exposed and non-exposed in cohort 
studies, or cases and controls in case-control studies. Differential 
misclassification can give rise to bias affecting the results in any direction. We 
believe that our standardized protocol, interviews, and registry data prohibited 
differential misclassification in our studies.  
 
Non-differential misclassification is when exposure and covariates are not 
assigned properly, but if this happens in a non-structural manner then cases, 
controls, exposed and non-exposed are affected to the same extent. Non-
differential misclassification usually causes the results to approach the null-
hypothesis.  
 
We do not believe we had any misclassification of the CKD outcome in the case-
control study because nephrologists were involved in the diagnostic assignment. 
The thorough information at inclusion on analgesic exposures (which included 
both prescribed and non-prescribed use), occupational exposures and other 
covariates minimized the risk for substantial misclassification. The information 
on analgesic use during follow-up was however difficult to retrieve from the 
medical records, and potentially subject to non-differential misclassification.  
Therefore we chose a restricted approach in the analysis (II), comparing only 
subjects with regular use both at inclusion and during follow-up, to subjects with 
no analgesic at inclusion or during follow-up. In the occupational lead 
investigation there is a certain risk of non-differential misclassification. The risk 
of misclassification is related to the reliability of the expert rating method. This 
method, although not perfect, is believed to be the best method to assess 
occupational exposures retrospectively in community based investigations.[236] 
We tried to improve misclassification by the combination of experts and self-
reported information on work tasks, duration, frequency, ventilation, and 
protective equipment, which has been shown to increase sensitivity. We also tried 
to validate our method by doing another expert rating among 53/52 randomly 
selected cases/controls up to three years after the first. The kappa-value for 
agreement between the two analyses was 0.87, which is almost perfect. In the 
study of rare exposures (like lead) a high specificity is needed to reduce the 
possibility for misclassification. In earlier studies the specificity for the expert 
rating method has been high (0.91-0.98).[235] In studies of occupational 
exposures it is found that the more exposed a subject is (high level), the more 
likely is it that he/she is classified correctly. In our sub-analysis of those with the 
highest exposure we did not see any higher risk of CKD or higher progression 
rate compared to the non-exposed.   
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To validate our use of co-morbid conditions from the medical records we 
analyzed the kappa statistics comparing the information in the medical records 
with self-reported information given at the interview. The agreement was 97% 
(ĸ=0.94) for presence of diabetes. We also had self-reported information on 
angina, which we compared to our registration of coronary heart disease from the 
record. Here the agreement was slightly lower, 91% (ĸ=0.69). Our overall 
interpretation is that the medical records gave valid information on the different 
co-morbid conditions. 
 
In the progression studies (II, III) we acknowledge that there is a risk of non-
differential misclassification of the outcome. Here we base our estimates on 
estimated GFR from the MDRD equation. One of the strengths is that we rely 
upon serial measurements of eGFR and that our main outcome, except in paper 
IV, is progression, not the eGFR values per se. The S-Cr values were analyzed at 
different chemical laboratories all over Sweden and not in a standardized manner. 
When the study started the Jaffe method was used, but over the following years 
some laboratories may have used the enzymatic method for some periods. 
Although there is a difference in serum creatinine with the two methods before 
the standardized assay was introduced, the resulting bias after introduction into 
the GFR estimating equation is likely to be small. At the level of serum creatinine 
where patients started dialysis the difference in eGFR (caused by the use of 
different methods) is 0-1 ml/min/1.73 m2. The advantage with a progression rate 
outcome is that even though creatinine calibration differed slightly between the 
laboratories, most patients had their tests taken at the same place. The inter-
measurement variation is thus most likely very small. In 2003 the laboratories 
started to use the standardized calibration, regardless of whether they used the 
enzymatic method or not. Patients initiating dialysis after the calibrated method 
was introduced have somewhat lower last eGFR compared to those who initiated 
dialysis before. The differences are, however, small in the range of S-Cr the 
patients of the cohort had. A 57-year-old man with S-Cr 800µmol/l has an eGFR 
of 6ml/min/1.73 m2 regardless of whether the standardized method was used or 
not. The difference was 1ml/min/1.73 m2 at S-Cr values 300-700µmol/l. In our 
data, we find statistical associations for most of the previous known risk factors 
for disease progression (age, sex, smoking, diabetes, blood pressure, and 
albuminuria). This speaks, in our opinion, against major non-differential 
misclassification of the outcome. We have been careful not to extend our 
analyses to subgroups since the in-born bias from the MDRD equation may be 





Statistical precision is achieved if the random sampling results in point estimates 
that are close. Information on precision is obtained from the confidence intervals. 
Results may have a high precision but nevertheless be biased and so invalid. The 
size of the standard error is dependent on the size of the population, the number 
of exposed, the number of individuals who develop the measured outcome, and 
the distribution of the exposed and events across the study population. Due to the 
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large number of participants in our cohort, as well as the number of events, we 
have good precision in most of our survival analyses. In the analyses of lead 
exposure about 10% of the patients in the cohort were exposed. At this exposure 
level the case-control study is powered to detect a 40-50% risk increase of CKD 
incidence (OR ~1.5). Lower risks may not have been detected, but this is also a 
lesser problem in absolute terms. In the highest exposure groups there were only 
a few subjects which limit the precision further. The same applies to the analysis 
of lead exposure as a risk factor for different primary renal diseases where 
limited precision prohibited us from any elaborate interpretation of the results. 
  
 
6.2 FINDINGS AND IMPLICATIONS 
 
 
6.2.1 Risk of Renal Replacement therapy and Mortality (I, IV) 
 
Incident patients with severe CKD (Stage 4-5) in Sweden have a high probability 
of progressing to ESRD and dialysis. In our population-based study, 82% of the 
patients eventually initiated RRT. Although all patients had severe renal failure at 
inclusion, the median time to RRT initiation was 2.2 years. International 
comparisons show that the prevalence of CKD Stage 3 far outnumbers that of 
CKD Stage 4-5[12]. We demonstrate that the proportion of patients with a 
progressive disease seems to be higher for patients who have reached eGFR 
around 20ml/min/1.73m2. We found that the risk for RRT was greatest among the 
youngest patients and those with diabetic nephropathy indicating that these 
patients will benefit more from timely referral to a nephrologist and preparation 
of vascular access. Another implication of our results would be to stress the 
importance of finding and treating patients with earlier stages of CKD since it 
seems too late to prevent future need for dialysis for most patients with eGFR 20 
ml/min/1.73m2. Although 10% of the patients died before RRT was initiated, the 
cause of death was usually not uremia but cardiovascular diseases. We did not 
find any evidence of a large number of untreated patients dying from uremia as 
has been speculated upon in earlier articles.[246] Patients with the highest risk of 
death were those of high age, low BMI, diabetes nephropathy, high cumulative 
co-morbidity score, and high level of albuminuria. Environmental factors such as 
smoking and alcohol intake showed no independent effect on mortality after 
adjustments for other related factors. Our findings imply that albuminuria is a 
strong prognostic factor, both for risk of RRT and for mortality – long after 
dialysis has been initiated. These results are in line with those of other 
researchers who have shown that level of albuminuria affects the cardiovascular 
mortality also in otherwise healthy individuals[102, 103]. Interestingly, we 
demonstrate that this applies also to patients with severe renal failure where the 
level of albuminuria may serve as a marker of the vascular/endothelial 






6.2.2 Risk factors for progression of Chronic Kidney Disease 
(II) 
  
The median progression rate (-5.1 ml/min/1.73 m2 per year) in our unselected 
population-based cohort of CKD patients in Sweden was remarkably similar to 
progression rates estimated in other more selected cohorts. It is however worth 
noting that the follow-up of this study was undertaken during a time (1996-2003) 
when the use of ACE-inhibitors was restricted to certain risk groups and the 
awareness of a strict anti-hypertensive management were not as profound as 
today. Among the risk factors for decline in eGFR we could confirm several of 
the previously known risk factors such as gender, elevated blood pressure and 
proteinuria. We also saw that presence of diabetes and low plasma albumin was 
associated with a faster progression rate, although the later association 
disappeared after correction for albuminuria. At this stage of disease, other life-
style related risk factors such as smoking and alcohol consumption did not seem 
to affect the progression rate. Thus, the major effort to retard disease progression 
among patients with Stage 4-5 CKD should be focused on treatment of 
hypertension and proteinuria. Treatment with ACE inhibitors/ARB has been 
demonstrated to slow the progression rate in selected patients with more 
preserved renal function.[47] In our study however, treatment with ACE 
inhibitors/ARB was not independently associated with a slower progression rate. 
On the contrary, in multivariate analyses we saw a faster decline in eGFR with 
such treatment. This relationship is difficult to interpret in the observational 
setting since the choice to treat a patient with ACE/ARB to a large extent is 
subjected to confounding by indication and since the treatment itself tends to 
increase S-Cr.  
 
 
6.2.3 Analgesic drug use and risk for decline in estimated GFR 
(II) 
 
Contrary to our previous beliefs, we found that neither acetaminophen nor aspirin 
use was related to a faster decline in eGFR. Although previous observational data 
have been divergent, the case-control study from our own reseach group showed 
a significantly increased risk with both acetaminophen and aspirin use.[185] The 
associations in the formar study were strongest for acetaminophen where the OR 
continued to be significantly elevated when subtracting exposure ten years before 
the study inclusion. For asprin, the association weakened in this “lagged” 
analysis. In our 5-7 years of follow-up of the same patients, the decline in eGFR 
was no different for acetaminophen users compared to non-users, and a slightly 
protective effect was noted among users of low-dose aspirin. Restricting the 
analysis to various subgroups did not change the results to any great extent. The 
results of our study (II) were first regarded with some skepticism by editors and 
reviewers, but other recent studies have come to the same conclusion[247, 248]. 
Our interpretation is that nephrologists may continue to use acetaminophen and 
   61 
low-dose aspirin for patients with CKD Stage 4-5 without risking a faster 
progression or initiation of RRT. The difference in our results compared to the 
case-control study may be that the mechanism initiating the first renal damage is 
different from that causing a more rapid progression. It may also be that the 
results in the case-control study still were influenced by protopathic bias, 
although precautions had been made to minimize this in the study design. We 
also acknowledge that there is some risk of non-differential misclassification 
affecting the results of our follow-up study. The number of exposed in the highest 
category were few, and this means lower precision. Moreover, based on our 
results, one may hypothesize that low-dose aspirin could be used to prevent 
disease progression among certain CKD risk groups. This must however be 
further evaluated with a proper randomized controlled trial.  
 
 
6.2.4 Occupational lead exposre and risk for CKD, RRT and 
decline in estimated GFR (III) 
 
Workers who had been occupationally exposed to lead did not develop CKD to a 
greater extent than the age and sex-matched general population. The OR was very 
close to one after multiple adjustments were made for confounding factors such 
as age, sex, alcohol consumption, diabetes, level of education and BMI. Neither 
did patients occupationally exposed to lead progress faster nor start RRT more 
often compared to non-exposed. Sub-group analyses restricted to those exposed 
at the highest levels (more than 50% of the Occupational Exposure Limit for at 
least five years) did not change the interpretation of no effect of lead exposure on 
renal function. The exposure levels in Sweden are quite low though. In a Swedish 
occupational cohort the mean blood lead level was 31.8µg/dL for workers who 
were exposed daily at a lead smelter factory[249]. The blood lead levels in the 
few other studies associated with renal damage have often been more than 
80µg/dL[212, 214, 250]. In Sweden, workers who are occupationally exposed to 
lead check their PbB regularly and are removed from exposure if the levels rise 
above 43µg/dL[251]. Our study implies that the present blood-lead limits in 
Sweden are defined at a level that precludes severe kidney complications. 
However, our study says nothing about other possible health effects seen with 
lead exposure at these levels. In addition, we confirmed a relationship for lead 




6.2.5 Survival and timing of dialysis initiation (IV) 
 
Our data confirm that CKD patients have a high mortality both before and after 
dialysis initiation. To our knowledge, our study is the first to compare survival 
rates before and after start of dialysis. We show that mortality increases with 
declining eGFR, and that the highest mortality is when eGFR moves below 7.5 
ml/min/1.73m2. In spite of the increasing mortality before dialysis, the timing of 
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dialysis initiation does not significantly affect survival. We see no survival 
benefit from earlier start of dialysis. Our results thus are coherent with those of 
the recently published RCT in which there was no difference in survival between 
the early and late dialysis group[162]. However, it is worth noting that accoring 
to the MDRD equation, their level of eGFR at dialysis initiation was higher than 
the mean level in our study. The early group in the IDEAL-study started dialysis 
at 9.0 ml/min/1.73m2 compared to 7.2 ml/min/1.73m2 in the late start group. In 
our study, the eGFR was 10.8 and 5.5 ml/min/1.73m2 at dialysis initiation for 
early and late starters respectively. Thus, although the difference between the 
groups was larger in our study, there was still no benefit from early initiation of 
dialysis. On the contrary, there was a small non-significant survival benefit from 
late start. Maybe the reason lies in the increased mortality seen after dialysis 
initiation. Of course, there may be a selective transfer of “sicker” patients into the 
dialysis group, but it could be that the dialysis procedure is demanding and 
increases inflammation and risk of arrhythmia. Our results show that although we 
save the patients from uremic death, our substitute treatment (dialysis) does not 
improve mortality. Based on our observations, a timely start of dialysis (where 
the survival benefits from dialysis out-weigh complications from treatment) is 
around eGFR 7.5 ml/min/1.73m2. 
 
We can also demonstrate that the progression rate is strikingly related to the 
timing of dialysis initiation. A patient with a faster progression rate has a greater 
probability of starting dialysis at lower eGFR than a patient with a more slowly 
progressing disease. Although most of the patients were already recognized at a 
renal clinic, there is always a delay between the recognition of the future need for 
RRT and the actual initiation of the dialysis process. First, there is the need to 
prepare the patient psychologically – not everyone wants to realize their need 
before they start to feel more distict symptoms. Then there is the need for 
vascular access or peritoneal cathether surgery, which sometimes delays the 
process. Thus, there are many reasons why the individual progression rate 
determines the timing of dialysis initiation. The progression rate is also 
independently associated to mortality, even after RRT is initiated. This 
relationship is more difficult to understand, but perhaps the progression rate is a 
marker of the severity of the disease that goes beyond albuminuria. The results of 
our studies indicate that the progression rate is another marker that predicts the 
long-term prognosis of CKD stage 4-5 patients.  
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6.3 FUTURE RESEARCH 
 
In our study, we saw that patients who used low-dose aspirin regularly progressed 
somewhat more slowly. Other cohort studies have indicated the same results. 
Today, low-dose aspirin is used as secondary prevention against ischemic heart 
disease. Whether low-dose aspirin really does reduce decline in glomerular 
filtration rate among CKD patients in general or among those with 
glomerulonephritis, is not well studied.  To investigate this association in the 
observational setting would require follow-up of a large number of patients with 
early stages of CKD. The problem is however confounding by indication. The 
only way to know if low dose aspirin is beneficial is to conduct a proper 
randomized controlled trial.  
 
Another question raised by our research is whether our results on lead exposure 
also apply to occupational cohorts. The number of lead exposed in our CKD 
cohort was only about 10%. Few exposed means poor precision, especially in the 
subgroup analyses. Information on PbB has been collected in Sweden among 
occupational lead workers for a couple of decades. The values are kept in a 
register at Arbetsmiljöverket. Linking these data (by using the personal 
identification numbers) to the Swedish Renal Registry would provide further 
knowledge of the risk of ESRD associated with different PbB-levels. We have 
also information on lifetime cumulative organic solvent exposure that we intend 
to analyze with regard to progression of eGFR and possibly by linkages to the 
SRR. There are conflicting data of the influence of organic solvents on the 
progression rate and development of CKD. Whereas some studies indicate that 
organic solvents increase the progression rate among certain primary 
glomerulonephritis, [252, 253] others fail to demonstrate the same 
relationship.[254]  
 
The renal registries in Sweden are important tools making high quality 
epidemiological research possible. These registries could be further developed to 
facilitate follow-up of large CKD groups. It is important to link the renal 
registries to databases with biologic material, such as kidney biopsies and blood, 
to increase the translational research. One interesting research question is if older 
patients benefit from RRT or if these patients are better managed with 
conservative treatment. Using the CKD registry it would be possible to define an 
eGFR (for example 10 ml/min/1.73m2) where follow-up is started, and then 
analyze survival for those treated conservatively versus those treated with 
dialysis. It would also be possible to apply advanced statistical models[255] 
(marginal structure models) and adjust for repeated information on co-morbidity 
and laboratory parameters. Our research has demonstrated that most patients with 
eGFR <20 ml/min/1.73m2 eventually start RRT.  Another interesting challenge 
would be to develop a decision-making model to determine the risk factors for 
future progressive renal disease. Such a model would make it easier to determine 
which Stage 3 CKD patients in our aging population would most benefit from 







I. Most patients with eGFR <20 ml/min/1.73m2 eventually start RRT. 
Gender, elevated blood pressure and proteinuria are the most important 
determinats of future need for dialysis. Risk factors for early death are 
age, low BMI, diabetes nephropathy, high cumulative co-morbidity 
score, and high level of albuminuria. 
 
II. Use of acetaminophen or asprin does not increase the decline in 
estimated renal function for patients with stage 4-5 CKD. 
 
III. Low level occupational lead exposure does not cause advanced CKD 
or a faster decline in estimated renal function for patients with stage 4-
5 CKD. 
 
IV. Early initiation of dialysis does not improve survival. Mortality 
increases below estimated GFR 7.5 ml/min/1.73m2 and increases 
further after initiation of dialysis treatment. 
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